var title_f4_41_4752="Pathway of NRTI induced MT";
var content_f4_41_4752=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Simplified mechanism to show the pathway of NRTI induced mitochondrial toxicity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 403px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When NRTIs inhibit DNA polymerase gamma, all mtDNA encoded proteins will ultimately be missing in the new generation of mitochondria, which then will only contain nDNA encoded proteins.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kees Brinkman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_41_4752=[""].join("\n");
var outline_f4_41_4752=null;
var title_f4_41_4753="Levosimendan: International drug information";
var content_f4_41_4753=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Levosimendan: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4369844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Simdax (ES, FI, NO, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vasodilator",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of congestive heart failure (CHF)",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: I.V.: Loading dose: 6-24 mcg/kg over 10 minutes followed by a continuous infusion of 0.05-0.2 mcg/kg/minute, adjusted according to response.",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: 2.5 mg/mL (5 mL, 10 mL)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10469 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-4327E6E395-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_41_4753=[""].join("\n");
var outline_f4_41_4753=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4369844\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979317\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979319\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979316\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821111\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979318\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10469\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10469|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_41_4754="CDC weight for length boys 0 to 36 months";
var content_f4_41_4754=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Weight-for-length percentiles, boys, birth to 36 months, CDC growth charts: United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 672px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Developed by the National Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_41_4754=[""].join("\n");
var outline_f4_41_4754=null;
var title_f4_41_4755="The prevalence and control of hypertension";
var content_f4_41_4755=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The prevalence and control of hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/41/4755/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/41/4755/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/41/4755/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/41/4755/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/41/4755/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/41/4755/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/41/4755/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Health and Nutrition Examination Survey (NHANES) data has provided important epidemiologic information on the prevalence and control of hypertension in the United States between 1960 and 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4755/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Overall, the prevalence is higher in older individuals, non-Hispanic blacks, and women (",
"    <a class=\"graphic graphic_figure graphicRef66935 \" href=\"UTD.htm?7/4/7247\">",
"     figure 1",
"    </a>",
"    ). The prevalence of hypertension in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It remains unclear why non-Hispanic blacks are more likely to become hypertensive. Both genetic and environmental factors are probably important, one of which may be a greater likelihood of low birth weight, which appears to predict higher pressures in adulthood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39477?source=see_link\">",
"     \"Possible role of low birth weight in the pathogenesis of essential hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NHANES data from 2007 to 2008 and United States Census bureau information demonstrated a 28 to 30 percent prevalence of hypertension in the 18 year and older population of the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4755/abstract/2,3,5\">",
"     2,3,5",
"    </a>",
"    ]. This translates into approximately 65 million hypertensives in the adult population in the United States, which is substantially higher than the 43.2 million estimate derived from the 1988-1991 NHANES-III survey [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4755/abstract/1,3,5\">",
"     1,3,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One possible explanation for the increased prevalence of hypertension reported in the latest survey data is that, over the last decade, there has been a marked increase in obesity and average body mass index [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4755/abstract/2\">",
"     2",
"    </a>",
"    ]. It is estimated, for example, that one-half of the relative increased prevalence of hypertension may be due to an increased weight of the average individual.",
"   </p>",
"   <p>",
"    A higher prevalence of hypertension has also been found in other industrialized societies. In surveys similar to the United States NHANES performed in Canada and six European countries, the age- and sex-adjusted prevalence of hypertension (defined as",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg or higher) were 28 and 44 percent in North American and European countries, respectively (",
"    <a class=\"graphic graphic_figure graphicRef66935 \" href=\"UTD.htm?7/4/7247\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4755/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The estimated global prevalence of hypertension is high. In a review, pooled data suggested that 26 percent of the world adult population (972 million) had hypertension in the year 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4755/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CONTROL OF HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Worldwide, hypertension is not adequately controlled [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4755/abstract/8\">",
"     8",
"    </a>",
"    ]. Poor control is even observed in hypertension units [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4755/abstract/9\">",
"     9",
"    </a>",
"    ]. Consider the following observations from NHANES data [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4755/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      72 percent of patients with hypertension were being treated.",
"     </li>",
"     <li>",
"      69 percent of the patients who were being treated had adequate blood pressure control, defined as a blood pressure below",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg.",
"     </li>",
"     <li>",
"      Overall, 50 percent of adults with hypertension had controlled blood pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    NHANES estimated that control of hypertension was achieved in 46, 53, and 44 percent of non-Hispanic blacks, whites, and Mexican-Americans, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4755/abstract/3\">",
"     3",
"    </a>",
"    ]. In one review of data from numerous sources, the prevalence of controlled hypertension ranged from as low as 11 percent among patients with chronic kidney disease in NHANES, to as high as 60 percent among individuals enrolled in health care plans [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4755/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple factors contribute to the low incidence of adequate control, including resistance to therapy. However, the most commonly uncontrolled patients are elderly, male, black, and those not seen by a physician in the last year [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4755/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the large numbers of individuals with uncontrolled hypertension, sequential information from the NHANES survey results suggested that control of hypertension has increased substantially over the past two decades, from 29 percent in 1988 to 50 percent in 2008 (",
"    <a class=\"graphic graphic_table graphicRef82423 \" href=\"UTD.htm?33/26/34219\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4755/abstract/2,3,12\">",
"     2,3,12",
"    </a>",
"    ]. This improvement in hypertension control is due to improvements in both awareness (73 to 81 percent) and treatment (55 to 72 percent).",
"   </p>",
"   <p>",
"    Similarly, data from the Veterans Administration suggest that hypertension control rates have risen substantially [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4755/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, an analysis of the Framingham Heart Study suggest that the increasing use of antihypertensive medications in patients with hypertension has lowered the incidence of left ventricular hypertrophy, a major risk factor for cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4755/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H289920563\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NHANES data from 2007 to 2008 and United States Census bureau information demonstrated a 28 to 30 percent prevalence of hypertension in the 18 year and older population of the United States. This translates into approximately 65 million hypertensives in the adult population in the United States. The age- and sex-adjusted prevalence of hypertension is 28 and 44 percent in Canada and Europe, respectively. Overall, about 26 percent of adults worldwide (972 million people) have hypertension.",
"     </li>",
"     <li>",
"      Overall, 50 percent of adults with hypertension in the United States have their blood pressure controlled, defined as a blood pressure below",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg. This rate of control has increased substantially over the past two decades, from 29 percent in 1988 to 50 percent in 2008.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4755/abstract/1\">",
"      Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4755/abstract/2\">",
"      Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4755/abstract/3\">",
"      Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4755/abstract/4\">",
"      Centers for Disease Control and Prevention (CDC). Vital signs: prevalence, treatment, and control of hypertension--United States, 1999-2002 and 2005-2008. MMWR Morb Mortal Wkly Rep 2011; 60:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4755/abstract/5\">",
"      Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 2004; 44:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4755/abstract/6\">",
"      Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289:2363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4755/abstract/7\">",
"      Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4755/abstract/8\">",
"      Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med 2007; 167:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4755/abstract/9\">",
"      Banegas JR, Segura J, Ruilope LM, et al. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension 2004; 43:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4755/abstract/10\">",
"      Wang TJ, Vasan RS. Epidemiology of uncontrolled hypertension in the United States. Circulation 2005; 112:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4755/abstract/11\">",
"      Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001; 345:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4755/abstract/12\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4755/abstract/13\">",
"      Fletcher RD, Amdur RL, Kolodner R, et al. Blood pressure control among US veterans: a large multiyear analysis of blood pressure data from the Veterans Administration health data repository. Circulation 2012; 125:2462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4755/abstract/14\">",
"      Mosterd A, D'Agostino RB, Silbershatz H, et al. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med 1999; 340:1221.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3851 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-0B08567BAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_41_4755=[""].join("\n");
var outline_f4_41_4755=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H289920563\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CONTROL OF HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H289920563\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3851\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3851|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/4/7247\" title=\"figure 1\">",
"      Prev htn in men women in US",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3851|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/26/34219\" title=\"table 1\">",
"      Hypertension awareness and Rx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39477?source=related_link\">",
"      Possible role of low birth weight in the pathogenesis of essential hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_41_4756="Acute lupus generalized 1";
var content_f4_41_4756=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Acute cutaneous lupus erythematosus (ACLE)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     A morbilliform eruption involving the sun-exposed V area of the neck and upper chest in a patient with ACLE.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_41_4756=[""].join("\n");
var outline_f4_41_4756=null;
var title_f4_41_4757="Intravascular lymphoma";
var content_f4_41_4757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F62103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F62103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intravascular lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 336px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The blood vessel shown in the center of this section is lined with lymphoma cells (arrows), with red blood cells in the lumen. This tumor can potentially be mistaken for a vascular (endothelial) neoplasm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_41_4757=[""].join("\n");
var outline_f4_41_4757=null;
var title_f4_41_4758="Overview of insomnia";
var content_f4_41_4758=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of insomnia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/41/4758/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/41/4758/contributors\">",
"     Michael H Bonnet, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/41/4758/contributors\">",
"     Donna L Arand, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/41/4758/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/41/4758/contributors\">",
"     Ruth Benca, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/41/4758/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/41/4758/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/41/4758/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with insomnia have impaired daytime function due to difficulty initiating sleep, difficulty maintaining sleep, chronically nonrestorative sleep, or poor quality sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/1\">",
"     1",
"    </a>",
"    ]. This occurs despite having adequate time and opportunity for sleep.",
"   </p>",
"   <p>",
"    This topic provides a general overview of insomnia, including its definition, epidemiology, clinical features, and consequences. The types, diagnostic evaluation, and management of insomnia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9561?source=see_link\">",
"     \"Types of insomnia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41541?source=see_link\">",
"     \"Clinical features and diagnosis of insomnia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link\">",
"     \"Treatment of insomnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insomnia is present when all three of the following criteria are met [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A complaint of difficulty initiating sleep, difficulty maintaining sleep, or waking up too early. Alternatively, sleep that is chronically nonrestorative or poor in quality.",
"     </li>",
"     <li>",
"      The above sleep difficulty occurs despite adequate opportunity and circumstances for sleep.",
"     </li>",
"     <li>",
"      The impaired sleep produces deficits in daytime function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Insomnia is often confused with short duration sleep and sleep deprivation, which are described below. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TYPES OF INSOMNIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of different classification systems have been proposed for insomnia. The most detailed classification system is the International Classification of Sleep Disorders, Second Edition (ICSD-2) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11301?source=see_link\">",
"     \"Classification of sleep disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ICSD-2 classification system categorizes the following types of insomnia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute insomnia, also called adjustment insomnia, short-term insomnia, stress-related insomnia, or transient insomnia",
"     </li>",
"     <li>",
"      Inadequate sleep hygiene",
"     </li>",
"     <li>",
"      Psychophysiological insomnia, also called primary insomnia, chronic insomnia, learned insomnia, or conditioned insomnia",
"     </li>",
"     <li>",
"      Idiopathic insomnia, also called childhood onset insomnia or life-long insomnia",
"     </li>",
"     <li>",
"      Paradoxical insomnia, also called sleep state misperception, subjective insomnia, pseudoinsomnia, and sleep hypochondriasis",
"     </li>",
"     <li>",
"      Insomnia associated with a medical condition, psychiatric disorder, neurologic disease, sleep disorder, medication, or drug use",
"     </li>",
"     <li>",
"      Unspecified insomnia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The types of insomnia are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9561?source=see_link\">",
"     \"Types of insomnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ICSD-2 classification system does not include the terminology \"secondary insomnia.\" This reflects the belief that insomnia is more often a distinct disorder that coexists with medical or psychiatric disorders, rather than as a consequence of these conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insomnia is one of the most common medical complaints. Prevalence estimates vary according to the study design and definition of insomnia used [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A survey of primary care patients found that 69 percent had insomnia [",
"      <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/4\">",
"       4",
"      </a>",
"      ]. The insomnia was reported as occasional by 50 percent and chronic by 19 percent.",
"     </li>",
"     <li>",
"      A national survey of noninstitutionalized adults found that 35 percent reported insomnia during the course of the previous year [",
"      <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/5\">",
"       5",
"      </a>",
"      ]. Nearly half described the insomnia as serious.",
"     </li>",
"     <li>",
"      A review of 50 studies found that approximately 10 percent of individuals develop chronic insomnia with related daytime consequences [",
"      <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prevalence of insomnia increases with age. In one study of elderly individuals, 57 percent had complaints consistent with insomnia and only 12 percent reported normal sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/7\">",
"     7",
"    </a>",
"    ]. Late-life insomnia is often persistent and may prompt self-medication with over-the-counter sleep aids or alcohol [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adult women report insomnia about 50 percent more often than men [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/5\">",
"     5",
"    </a>",
"    ]. There is also a higher prevalence of insomnia among persons who are unemployed, divorced, widowed, separated, or of lower socioeconomic status [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that 7 percent of adults develop insomnia each year and 30 percent develop some symptoms of insomnia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/9\">",
"     9",
"    </a>",
"    ]. Insomnia may be more common among individuals with a psychological vulnerability to insomnia. Variables associated with the onset of insomnia include a previous episode of insomnia, a family history of insomnia, a predisposition toward being more easily aroused from sleep, poorer self-rated health, and more body pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with insomnia typically complain about difficulty falling asleep or staying asleep. They may also describe variable sleep, such as one or several nights of poor sleep followed by a night of better sleep.",
"   </p>",
"   <p>",
"    The degree of subjective sleep disturbance reported varies, but typically includes 30 or more minutes to fall asleep or a total sleep time of six hours or less on three or more nights per week. Occasionally, reports may be as severe as an inability to sleep at all for several nights. Many patients can identify factors that may be interfering with their sleep, such as travel, noise, family imposition, pain, stress, or nocturia.",
"   </p>",
"   <p>",
"    Impaired daytime function is reported by most patients. The following are among the most common complaints [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fatigue or malaise",
"     </li>",
"     <li>",
"      Poor attention or concentration",
"     </li>",
"     <li>",
"      Social or vocational dysfunction",
"     </li>",
"     <li>",
"      Mood disturbance",
"     </li>",
"     <li>",
"      Daytime sleepiness",
"     </li>",
"     <li>",
"      Reduced motivation or energy",
"     </li>",
"     <li>",
"      Increased errors or accidents",
"     </li>",
"     <li>",
"      Tension, headache, or gastrointestinal symptoms",
"     </li>",
"     <li>",
"      Ongoing worry about sleep",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with psychophysiological insomnia are often worried that their lack of adequate sleep will result in significant compromise of their ability to function during the day in both social and professional settings. This concern can create a cycle that worsens the insomnia. Specifically, when patients are unable to fall asleep rapidly, they become increasingly concerned about their performance the following day. This makes it more unlikely that the patient will be able to fall asleep and sleep well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a patient presents with insomnia, the presence of a variety of medical conditions, psychiatric disorders, neurologic diseases, sleep disorders, medications, and other substances associated with insomnia should be explored. Insomnia is classified as \"insomnia associated with\" the coexisting condition if such a condition is identified. It is otherwise considered an independent disorder. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Types of insomnia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Insomnia is often confused with short duration sleep and sleep deprivation, but differs from each:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sleep for a short duration can be normal. Some individuals simply require less sleep and can sleep for a reduced number of hours without daytime complaints. Such individuals do not have insomnia.",
"     </li>",
"     <li>",
"      Sleep deprivation and insomnia are both characterized by a short duration of sleep and impaired daytime function. However, sleep deprivation differs from insomnia in that sleep deprivation is characterized by volitional sleep loss. Sleep deprived individuals will rapidly fall asleep if given the opportunity. Insufficient sleep is probably the most common cause of excessive sleepiness in the general population, affecting approximately one-third of normal adults. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4487?source=see_link\">",
"       \"Definition and consequences of sleep deprivation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians need to be alert to the possibility that a patient has insomnia because only 30 percent of patients with insomnia spontaneously report their sleep problem to the clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/10\">",
"     10",
"    </a>",
"    ]. The diagnostic evaluation of insomnia is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41541?source=see_link\">",
"     \"Clinical features and diagnosis of insomnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral and pharmacologic therapies are available for insomnia. The management of insomnia is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link\">",
"     \"Treatment of insomnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CONSEQUENCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Understanding the consequences of insomnia is important because the level of compromise that they create must be balanced against the risks of therapy whenever treatment is considered. This section describes the sequelae associated with insomnia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with insomnia have increased fatigue, sleepiness, confusion, tension, anxiety, and depression compared to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/11\">",
"     11",
"    </a>",
"    ]. Such dysphoria pervades other areas of life, causing patients with insomnia to report a decreased quality of life and degraded performance.",
"   </p>",
"   <p>",
"    Patients with insomnia have decrements in both medical and emotional aspects of life, as determined by a standard measure of quality of life, the Medical Outcomes Study Short Form (SF-36) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/12\">",
"     12",
"    </a>",
"    ]. The magnitude of the impairment was similar to that seen in patients with a chronic medical condition (eg, heart failure) or depression.",
"   </p>",
"   <p>",
"    Quality of life can also be measured by looking at employment measures, such as promotions and sick time. Patients with insomnia are less likely to receive promotions and more likely to have errors or accidents, to be absent from work, and to have more health-related consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. The poor work performance, increased medical issues, and increased emotional burden associated with insomnia increase costs to society [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with insomnia are almost universally concerned that their poor sleep has negative consequences on their performance of daily tasks and consistently report subjective performance deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/16\">",
"     16",
"    </a>",
"    ]. However, patients with insomnia tend to overestimate the magnitude of the performance deficit, just as they tend to overestimate the magnitude of their sleep deficits.",
"   </p>",
"   <p>",
"    Numerous studies have examined psychomotor performance in patients with insomnia compared to controls and the only consistent deficit found was a decrement in balance. However, about 20 percent of measures involving memory were significantly decreased in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Physiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic primary insomnia (ie, psychophysiological insomnia) is associated with physiological activation. A majority of studies have found large increases in measures of physiological activation, including cardiac, metabolic, hormone, and high frequency electroencephalographic (EEG) measures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/11\">",
"     11",
"    </a>",
"    ]. Studies have shown increased activity during sleep in hypothalamic areas and reduced hippocampal volume in patients with insomnia compared to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary insomnia is associated with sympathetic nervous system activation. This observation has led to the proposal that chronic insomnia may be associated with an increased risk of hypertension and cardiac disease, including myocardial infarction. Studies have supported these associations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]. Insomnia also frequently coexists with respiratory conditions, neurologic disorders, urinary disorders, pain disorders, and gastrointestinal disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Insomnia is also a strong predictor of the development of psychiatric disorders, such as depression, anxiety, and drug abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/26\">",
"     26",
"    </a>",
"    ]. Among patients with both insomnia and a mood disorder, approximately one-third developed insomnia prior to the mood disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/27\">",
"     27",
"    </a>",
"    ]. Similarly, a majority of alcoholics report sleeping problems prior to their alcohol dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/28\">",
"     28",
"    </a>",
"    ]. Insomnia is highly predictive of relapse in both depression and alcohol dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insomnia is often a persistent or recurrent condition. This was best illustrated by an observational study of 388 adults with insomnia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4758/abstract/31\">",
"     31",
"    </a>",
"    ]. The study found that insomnia lasted at least one year in 74 percent of the adults and at least three years in 46 percent. It was most likely to persist in women, older adults, and those with severe insomnia. The insomnia resolved in 54 percent of the adults, but eventually relapsed in 27 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/16/2306?source=see_link\">",
"       \"Patient information: Insomnia (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/24/28035?source=see_link\">",
"       \"Patient information: Insomnia treatments (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insomnia is considered present when all of the following three criteria are met (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Difficulty initiating sleep, difficulty maintaining sleep, waking up too early, chronically nonrestorative sleep, or poor quality sleep",
"     </li>",
"     <li>",
"      The sleep difficulty occurs despite adequate opportunity and circumstances for sleep",
"     </li>",
"     <li>",
"      There are related daytime complaints",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A number of different classification systems have been proposed for insomnia. The most detailed classification system is the International Classification of Sleep Disorders, Second Edition (ICSD-2). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Types of insomnia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Insomnia is one of the most common medical complaints. Patients with insomnia report difficulty falling asleep or staying asleep. They may also describe variable sleep, such as one or several nights of poor sleep followed by a night of better sleep. Such sleep-related complaints are accompanied by reports of impaired daytime function. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When a patient presents with insomnia, a variety of medical conditions, psychiatric disorders, neurologic diseases, sleep disorders, medications, and other substances associated with insomnia should be considered. Insomnia is classified as \"insomnia associated with\" the coexisting condition if such a condition is identified. It is otherwise designated as an independent disorder. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sequelae of insomnia include decreased quality of life, complaints of impaired daytime performance, medical comorbidities, and emotional comorbidities. While treatment can reverse insomnia-related decrements in quality of life, the extent to which it might improve other medical or emotional comorbidities is unknown. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Consequences'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     International classification of sleep disorders: Diagnostic and coding manual, 2nd ed, American Academy of Sleep Medicine, Westchester, IL 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/2\">",
"      National Institutes of Health. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. Sleep 2005; 28:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/3\">",
"      Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002; 6:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/4\">",
"      Shochat T, Umphress J, Israel AG, Ancoli-Israel S. Insomnia in primary care patients. Sleep 1999; 22 Suppl 2:S359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/5\">",
"      Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry 1985; 42:225.",
"     </a>",
"    </li>",
"    <li>",
"     Johnson EO. Epidemiology of insomnia: from adolescence to old age. In: Sleep Medicine Clinics: Insomnia, Roth T (Ed), Elsevier, Philadelphia 2006. p.305.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/7\">",
"      Foley DJ, Monjan AA, Brown SL, et al. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep 1995; 18:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/8\">",
"      Morphy H, Dunn KM, Lewis M, et al. Epidemiology of insomnia: a longitudinal study in a UK population. Sleep 2007; 30:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/9\">",
"      LeBlanc M, M&eacute;rette C, Savard J, et al. Incidence and risk factors of insomnia in a population-based sample. Sleep 2009; 32:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/10\">",
"      Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. Sleep 1999; 22 Suppl 2:S347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/11\">",
"      Bonnet, MH, Arand, DL. Consequences of insomnia. Sleep Med Clin 2006; 1:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/12\">",
"      Katz DA, McHorney CA. The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract 2002; 51:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/13\">",
"      L&eacute;ger D, Massuel MA, Metlaine A, SISYPHE Study Group. Professional correlates of insomnia. Sleep 2006; 29:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/14\">",
"      Ozminkowski RJ, Wang S, Walsh JK. The direct and indirect costs of untreated insomnia in adults in the United States. Sleep 2007; 30:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/15\">",
"      Daley M, Morin CM, LeBlanc M, et al. The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers. Sleep 2009; 32:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/16\">",
"      Vignola A, Lamoureux C, Bastien CH, Morin CM. Effects of chronic insomnia and use of benzodiazepines on daytime performance in older adults. J Gerontol B Psychol Sci Soc Sci 2000; 55:P54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/17\">",
"      Nofzinger EA, Buysse DJ, Germain A, et al. Functional neuroimaging evidence for hyperarousal in insomnia. Am J Psychiatry 2004; 161:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/18\">",
"      Riemann D, Voderholzer U, Spiegelhalder K, et al. Chronic insomnia and MRI-measured hippocampal volumes: a pilot study. Sleep 2007; 30:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/19\">",
"      Bonnet MH, Arand DL. Heart rate variability in insomniacs and matched normal sleepers. Psychosom Med 1998; 60:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/20\">",
"      Suka M, Yoshida K, Sugimori H. Persistent insomnia is a predictor of hypertension in Japanese male workers. J Occup Health 2003; 45:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/21\">",
"      Bonnet, MH, Arand, DL, Javaheri, S. Cardiovascular implications of poor sleep. Sleep Med Clin 2007; 2:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/22\">",
"      Vgontzas AN, Liao D, Bixler EO, et al. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep 2009; 32:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/23\">",
"      Fernandez-Mendoza J, Vgontzas AN, Liao D, et al. Insomnia with objective short sleep duration and incident hypertension: the penn state cohort. Hypertension 2012; 60:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/24\">",
"      Taylor DJ, Mallory LJ, Lichstein KL, et al. Comorbidity of chronic insomnia with medical problems. Sleep 2007; 30:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/25\">",
"      Walsh JK, Coulouvrat C, Hajak G, et al. Nighttime insomnia symptoms and perceived health in the America Insomnia Survey (AIS). Sleep 2011; 34:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/26\">",
"      Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 1989; 262:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/27\">",
"      Fava GA, Grandi S, Canestrari R, Molnar G. Prodromal symptoms in primary major depressive disorder. J Affect Disord 1990; 19:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/28\">",
"      Currie SR, Clark S, Rimac S, Malhotra S. Comprehensive assessment of insomnia in recovering alcoholics using daily sleep diaries and ambulatory monitoring. Alcohol Clin Exp Res 2003; 27:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/29\">",
"      Brower KJ, Aldrich MS, Robinson EA, et al. Insomnia, self-medication, and relapse to alcoholism. Am J Psychiatry 2001; 158:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/30\">",
"      Krystal, AD. Psychiatric comorbidity: the case for treating insomnia. Sleep Med Clin 2006; 1:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4758/abstract/31\">",
"      Morin CM, B&eacute;langer L, LeBlanc M, et al. The natural history of insomnia: a population-based 3-year longitudinal study. Arch Intern Med 2009; 169:447.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7684 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-3A23DB03CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_41_4758=[""].join("\n");
var outline_f4_41_4758=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TYPES OF INSOMNIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CONSEQUENCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Quality of life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Performance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Physiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Comorbidities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11301?source=related_link\">",
"      Classification of sleep disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41541?source=related_link\">",
"      Clinical features and diagnosis of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4487?source=related_link\">",
"      Definition and consequences of sleep deprivation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/16/2306?source=related_link\">",
"      Patient information: Insomnia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/24/28035?source=related_link\">",
"      Patient information: Insomnia treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=related_link\">",
"      Treatment of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9561?source=related_link\">",
"      Types of insomnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_41_4759="Management of ovarian cancer in pregnant women";
var content_f4_41_4759=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of ovarian cancer in pregnant women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/41/4759/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/41/4759/contributors\">",
"     Carolyn D Runowicz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/41/4759/contributors\">",
"     Molly Brewer, DVM, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/41/4759/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/41/4759/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/41/4759/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/41/4759/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/41/4759/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The care of a pregnant woman with cancer involves evaluation of sometimes competing maternal and fetal risks and benefits. It is a common assumption by both patients and physicians that if an ovarian cancer is diagnosed during pregnancy, treatment necessitates sacrificing the wellbeing of the fetus. However, in most cases, it is possible to offer appropriate treatment to the mother without placing the fetus at serious risk.",
"   </p>",
"   <p>",
"    The approaches described in this review attempt to balance maternal and fetal risks and benefits; they should be considered advisory and should not replace interdisciplinary consultation with specialists in maternal-fetal medicine, gynecologic oncology, and pediatrics, as well as imaging and pathology, as needed.",
"   </p>",
"   <p>",
"    Issues specifically pertaining to management of ovarian cancer diagnosed during pregnancy will be reviewed here. The management of ovarian cancer in nonpregnant women, as well as the clinical manifestations and diagnosis of ovarian cancer in pregnant women, are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"       \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link\">",
"       \"Epithelial ovarian cancer: Initial surgical management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link\">",
"       \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9192?source=see_link\">",
"       \"Clinical manifestations and diagnosis of ovarian cancer in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general consensus regarding management of adnexal masses in pregnancy is to surgically resect masses that have any of the following characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4759/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persist into the second trimester, and",
"     </li>",
"     <li>",
"      Are larger than 10 cm in diameter, or",
"     </li>",
"     <li>",
"      Have solid or mixed solid and cystic ultrasound characteristics highly suspicious for malignancy on imaging",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rationale for this approach is to diagnose malignancy, if present, at an early stage and to prevent complications such as adnexal torsion, rupture, or obstruction of labor in women who have benign ovarian tumors. Emergency surgery for management of a torsed or ruptured adnexal mass can lead to preterm delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4759/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal time for surgery during pregnancy is the early second trimester, for a number of reasons (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15482?source=see_link\">",
"     \"Management of pregnant women undergoing nonobstetric surgery\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Organogenesis is complete, thus minimizing the risk of drug-induced teratogenesis",
"     </li>",
"     <li>",
"      The hormonal function of the corpus luteum has been replaced by the placenta, so reduction in progesterone secretion from oophorectomy or cystectomy does not result in loss of the pregnancy",
"     </li>",
"     <li>",
"      The risk of pregnancy loss related to second trimester surgery is low",
"     </li>",
"     <li>",
"      Almost all functional cysts will have resolved by this time",
"     </li>",
"     <li>",
"      Spontaneous pregnancy losses due to intrinsic fetal abnormalities are likely to have already occurred and will not be erroneously attributed to the surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An adnexal mass identified incidentally at the time of cesarean delivery should be removed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4759/abstract/6\">",
"     6",
"    </a>",
"    ]. Complete surgical removal of the mass is preferred over aspiration and cytologic evaluation. In most cases when an ovarian cancer is detected, the patient will not have an appropriate incision for surgical staging. We recommend a frozen section of the resected neoplasm. If it is malignant, salpingo-oophorectomy can be performed and, postpartum, the patient is referred to a gynecologic oncologist for counseling, staging, and further treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREOPERATIVE STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, the preoperative workup for a pregnant woman with a pelvic mass can be limited to ultrasound imaging. If the ultrasound findings cannot distinguish between a possible pedunculated or degenerating leiomyoma and an ovarian neoplasm, we suggest obtaining magnetic resonance imaging (MRI). The more precise diagnosis afforded by MRI may allow the clinician to cancel planned exploratory surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4759/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9192?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and diagnosis of ovarian cancer in pregnancy\", section on 'Magnetic resonance imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A routine preoperative chest x-ray is unnecessary; however, if the history and physical examination suggest pulmonary disease, then a chest x-ray should be obtained with shielding of the",
"    <span class=\"nowrap\">",
"     abdomen/pelvis.",
"    </span>",
"   </p>",
"   <p>",
"    Although serum tumor markers are routinely drawn preoperatively when planning a laparotomy for management of a pelvic mass in nonpregnant women, we do not suggest this approach during pregnancy. Pregnancy associated pelvic masses are infrequently malignant, and as outlined above, the interpretation of these tumor markers varies with gestational age and comorbid conditions. If a malignancy is proven, then appropriate tumor markers may be drawn in the immediate postoperative period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9192?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical manifestations and diagnosis of ovarian cancer in pregnancy\", section on 'Tumor markers in ovarian malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SURGICAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;At laparotomy, the midline incision should be adequate to minimize the need to manipulate the gravid uterus while obtaining exposure to the adnexal mass. Although laparoscopy is an option, there are some technical issues. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Laparoscopy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Aggressive manipulation of the uterine fundus because the incision is too small could increase the risk of placental abruption, premature labor, and fetal loss. If a malignancy is suspected, a Pfannenstiel incision should be avoided as it would not provide sufficient exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediately after entry into the peritoneal cavity, peritoneal washings should be obtained for staging purposes in case the mass is malignant. The opposite adnexa should be carefully inspected and palpated for a contralateral adnexal mass. Contralateral ovarian biopsy is recommended if the ovary appears to be involved, but routine biopsy or wedge resection of a normal-appearing contralateral ovary is unwarranted.",
"   </p>",
"   <p>",
"    The most common findings at surgery are benign dermoid cysts and serous or mucinous cystadenomas. If the preoperative imaging and intraoperative gross findings are both consistent with a benign diagnosis, it is reasonable to attempt a cystectomy rather than perform a salpingo-oophorectomy. If the mass is larger than 10 cm, it may not be technically feasible to perform an ovarian cystectomy. If the mass is solid, has surface excrescences, is associated with ascites, or has other features suggesting malignancy, then ipsilateral salpingo-oophorectomy is appropriate. The mass should be sent for frozen section and the pathologist informed of the concurrent pregnancy.",
"   </p>",
"   <p>",
"    Resection of the contralateral ovary is not required unless bilateral disease is identified; this decision must await the frozen section analysis. All suspicious lesions should be biopsied.",
"   </p>",
"   <p>",
"    If the pathologist confirms a malignant tumor at frozen section, the surgeon should be prepared to complete an adequate surgical staging procedure and a gynecologic oncologist should be consulted. At cesarean delivery, any mass that appears suspicious for malignancy should be sent for frozen section and, if positive, full staging should be done. The general principles of the staging procedure for a malignant ovarian tumor are described in the table (",
"    <a class=\"graphic graphic_table graphicRef75194 \" href=\"UTD.htm?40/8/41099\">",
"     table 1",
"    </a>",
"    ) and in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link&amp;anchor=H15#H15\">",
"     \"Epithelial ovarian cancer: Initial surgical management\", section on 'Staging procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adequate surgical staging is of particular importance for stage I cancers (ie, those that are limited to the ovary) as many, but not all, of these neoplasms are adequately treated with surgery alone. In such cases, the need for postoperative adjuvant chemotherapy is determined by the histologic tumor type. Surgical staging (eg, sampling of lymph nodes) is less critical in the setting of obvious advanced disease (eg, stage",
"    <span class=\"nowrap\">",
"     IIIB/C",
"    </span>",
"    disease) as these tumors (with the exception of tumors of low malignant potential) will require chemotherapy to control metastases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/53/19287?source=see_link\">",
"     \"Chemotherapy of ovarian cancer in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33162?source=see_link\">",
"     \"Treatment of malignant germ cell tumors of the ovary\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tumors of low malignant potential do not usually require chemotherapy. Two types have been described, an atypical proliferative serous tumor that has benign behavior and a low grade serous carcinoma (noninvasive micropapillary serious carcinomas) that may be a precursor to invasive low grade serous carcinoma. Regardless of stage, chemotherapy is not generally recommended following diagnosis and staging. The use of chemotherapy for those that exhibit invasive peritoneal implants is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4759/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5128?source=see_link\">",
"     \"Ovarian tumors of low malignant potential\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a metastatic ovarian cancer is identified, cytoreduction should be attempted. The extent of surgical cytoreduction involves individual judgment, balancing the extent of surgery with the expected benefit. It is rare that removal of the gravid uterus is required for maximal cytoreductive surgery at the initial surgery, as it is possible to return for secondary cytoreduction following chemotherapy and successful completion of the pregnancy. This management strategy is not thought to adversely impact survival, although as a general rule, survival is poor for women who have late stage disease.",
"   </p>",
"   <p>",
"    The majority of women with ovarian germ cell tumors undergo maximal surgical cytoreduction before starting chemotherapy. The central role that initial surgery plays in ovarian germ cell tumors is in direct contrast to testicular germ cell tumors, where surgery is typically reserved for residual masses that remain after chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link\">",
"     \"Surgical management of advanced testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the importance of early surgical debulking to outcomes in this disease, the surgeon should keep in mind the sensitivity of these tumors to platinum-based chemotherapy when aggressive resection of metastatic disease is considered. With modern platinum-based adjuvant chemotherapy, approximately 70 percent of patients who present with advanced disease will respond to chemotherapy, even if they have residual disease remaining after cytoreductive surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33162?source=see_link\">",
"     \"Treatment of malignant germ cell tumors of the ovary\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hazard of overly aggressive surgery and delay in starting chemotherapy can be illustrated by a case report of a patient with a yolk sac tumor that was resected at 19 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4759/abstract/9\">",
"     9",
"    </a>",
"    ]. Chemotherapy was delayed because of the pregnancy and at 32 weeks of gestation, tumor recurrence necessitated a cesarean-hysterectomy and bowel resection with colostomy. Three weeks later, the colostomy was taken down and another suprahepatic tumor mass was resected. The patient was then given BEP for four cycles, but the course was complicated by a fecal fistula that developed at the colostomy site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the frequency of malignancy is low in pregnant patients with adnexal masses, laparoscopy can be performed to minimize recovery time and postoperative discomfort. Small series have reported outcomes of laparoscopy for management of adnexal masses in pregnancy. In one series, 17 patients were in the first trimester, 27 were in the second trimester, and four were in the third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4759/abstract/10\">",
"     10",
"    </a>",
"    ]. The procedure could not be completed in one patient due to adhesions and in another due to bleeding. In this series, the mean hospital stay was 3.8 days. Subsequent reports have confirmed that laparoscopy can be safely performed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4759/abstract/11\">",
"     11",
"    </a>",
"    ]. Most of the patients have been in the first or second trimester of their pregnancies.",
"   </p>",
"   <p>",
"    Although there is a theoretic concern that CO",
"    <sub>",
"     2",
"    </sub>",
"    insufflation with increased intraabdominal pressure could decrease uterine blood flow and result in fetal hypotension and hypoxia, the available small series have not reported adverse fetal outcomes. Furthermore, in a small study measuring feto-maternal blood flow, no reduction in blood flow was noted [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4759/abstract/12\">",
"     12",
"    </a>",
"    ]. There is a risk of uterine perforation by a trocar or Veress needle and injury to uterine blood vessels. Risk of injury to the gravid uterus may be lessened by a left upper quadrant insertion of the Veress needle and laparoscope. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8727?source=see_link\">",
"     \"Laparoscopic surgery in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Management of corpus luteum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Removal of the corpus luteum should be avoided prior to eight weeks of gestation because the corpus luteum is primarily responsible for progesterone production and maintenance of the pregnancy at this time [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4759/abstract/13\">",
"     13",
"    </a>",
"    ]. If the corpus luteum is removed prior to eight weeks, progesterone can be given as a 50 to 100 mg vaginal suppository every 8 to 12 hours or a daily intramuscular injection of 1 mL (50 mg) progesterone in oil. After eight weeks, the ovary gradually shifts progesterone production to the placenta (called the luteal-placental shift) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4759/abstract/14\">",
"     14",
"    </a>",
"    ]. As of 10 weeks of gestation, the placenta is the primary provider of progesterone so progesterone supplementation is no longer indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15482?source=see_link\">",
"     \"Management of pregnant women undergoing nonobstetric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY AND TIMING OF DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy may be indicated for treatment of cancer, including ovarian cancer, during pregnancy. Fortunately, having to start chemotherapy during pregnancy for ovarian cancer is an uncommon event. Although it may be lifesaving for the mother, chemotherapy has the potential to adversely impact the pregnancy. Concerns about administration of cytotoxic chemotherapy during pregnancy arise because chemotherapy preferentially kills rapidly proliferating cells, and the fetus represents a rapidly proliferating cell mass. The risks of chemotherapy administration during pregnancy depend on the drugs used and the gestational age of the fetus.",
"   </p>",
"   <p>",
"    All chemotherapy agents used in the treatment of epithelial and nonepithelial ovarian cancers are pregnancy category D, meaning that adverse effects have occurred in&nbsp;human fetuses exposed to the individual drugs. However, the risk of spontaneous abortion, fetal death, and major malformations varies with the specific agent used and the trimester of pregnancy; most risks are highest in the first trimester.",
"   </p>",
"   <p>",
"    In general, if chemotherapy is indicated and cannot be delayed, it is preferable to initiate chemotherapy in the second or early third trimester. Early delivery to avoid fetal exposure to maternal chemotherapy is reasonable if fetal lung maturity can be documented and the fetus is &ge;34 weeks of gestation. In this setting, the risks of prematurity are relatively low. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=see_link\">",
"     \"Incidence and mortality of the premature infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to chemotherapy of ovarian cancer in pregnant and lactating women is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/53/19287?source=see_link\">",
"     \"Chemotherapy of ovarian cancer in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREGNANCY TERMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to continue or terminate a pregnancy when ovarian cancer is diagnosed in the first trimester should be individualized and made by a fully informed woman in collaboration with her clinician. Early termination of pregnancy does not improve the outcome of ovarian cancer (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Prognosis'",
"    </a>",
"    below). In addition to the usual reasons for pregnancy termination, some factors that should be considered in women with ovarian cancer include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Whether she is willing to assume a possible risk of fetal toxicity or complications from ovarian cancer treatment during pregnancy.",
"     </li>",
"     <li>",
"      Her prognosis and ability to care for her offspring.",
"     </li>",
"     <li>",
"      The effect of ovarian cancer treatment on future fertility. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7977?source=see_link\">",
"       \"Overview of fertility and pregnancy in cancer survivors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     BREASTFEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytotoxic agents may reach significant levels in breast milk and thus breastfeeding while on chemotherapy is generally contraindicated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4759/abstract/15\">",
"     15",
"    </a>",
"    ]. The United States National Library of Medicine Drugs and Lactation Database (",
"    <a class=\"external\" href=\"file://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT\">",
"     LactMed",
"    </a>",
"    ) is an excellent resource for information on transfer of specific drugs into human milk and possible effects on the infant or on lactation, if known. Possible adverse effects include immune suppression, impaired growth, or association with carcinogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4759/abstract/16\">",
"     16",
"    </a>",
"    ]. We agree with the World Health Organization&rsquo;s recommendation against nursing while receiving chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4759/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE AND FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the pregnancy is complete, the cancer may be further treated without concern about fetal effects. Although chemotherapy has been given antepartum, there are essentially no pharmacokinetic data regarding the use of antineoplastic drugs during pregnancy. Renal function changes dramatically during the course of pregnancy and the puerperium. It is unknown if chemotherapy doses calculated using the methods regularly used for nonpregnant women are also optimal for pregnant women.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     Carboplatin",
"    </a>",
"    is usually dosed based on renal function.",
"   </p>",
"   <p>",
"    For women with advanced stage ovarian cancer being treated during pregnancy, it is prudent to consider completion of the hysterectomy and contralateral oophorectomy, as well as a secondary cytoreductive surgery at the conclusion of pregnancy. This approach was taken by a number of investigators who reported managing advanced epithelial ovarian cancer cases during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4759/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. Persistent disease was frequent: in four such patients, two had disease involving the adnexa [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4759/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], two involved the bowel [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4759/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], and one also involved the pelvic peritoneum, omentum, and appendix [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4759/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the patient has completed her initial treatment, her follow-up will be similar to other women with ovarian cancer. A typical follow-up regimen would involve physical examinations (including pelvic examination) and serum tumor marker assays repeated every two to four months for the first two years, spacing these out to every three to six months for three years, and then annually at the fifth year [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4759/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that pregnancy worsens the prognosis of ovarian tumors compared to nonpregnant patients matched for tumor histology, stage and grade. Approximately 75 percent of invasive ovarian malignancies in pregnant women are early stage disease. Due to the favorable mix of stage, grade, and histology, the five-year survival rate for ovarian tumors associated with pregnancy is between 72 and 90 percent. The presence of ascites at diagnosis implies advanced disease and poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4759/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One cohort study found that postpartum lactating women diagnosed with ovarian cancer had a poorer prognosis than women diagnosed before or during pregnancy, but the numbers of cases was small [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4759/abstract/24\">",
"     24",
"    </a>",
"    ]. This finding needs to be confirmed in larger studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical care of women who are diagnosed with an ovarian malignancy in the context of an ongoing pregnancy requires multidisciplinary consultation. Since many treatment decisions require balancing competing maternal and fetal risk, consultants with expertise in maternal-fetal medicine, gynecologic oncology, and pediatrics should work together to advise the pregnant woman and her family as the treatment is being planned. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical exploration is indicated for diagnosis and initial therapy. We suggest surgery be performed for ovarian masses that persist into the second trimester and are greater than 10 cm in diameter, or have solid or mixed solid and cystic ultrasound characteristics suspicious for malignancy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most cases, the preoperative staging workup for a pregnant woman with a pelvic mass can be limited to ultrasound imaging. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Preoperative staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnancy-associated ovarian tumors should be evaluated by a pathologist skilled in reading the pathologic findings in the context of the ongoing pregnancy. The pathologist should be informed of the coexistent pregnancy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During antepartum surgical staging and debulking, we suggest leaving as much of the reproductive tract in-situ as possible (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest that women found to have advanced stage epithelial ovarian cancer undergo completion of debulking of the reproductive organs at the conclusion of the pregnancy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Procedure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Postoperative care and follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Removal of the corpus luteum prior to eight weeks of gestation requires postoperative progesterone supplementation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Management of corpus luteum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early delivery to avoid fetal exposure to maternal chemotherapy is reasonable if fetal lung maturity can be documented and the fetus is &ge;34 weeks of gestation. In this setting, the risks of prematurity are relatively low. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Chemotherapy and timing of delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Breastfeeding is not advised for women who need chemotherapy in the postpartum period. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Breastfeeding'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4759/abstract/1\">",
"      Leiserowitz GS, Xing G, Cress R, et al. Adnexal masses in pregnancy: how often are they malignant? Gynecol Oncol 2006; 101:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4759/abstract/2\">",
"      Schmeler KM, Mayo-Smith WW, Peipert JF, et al. Adnexal masses in pregnancy: surgery compared with observation. Obstet Gynecol 2005; 105:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4759/abstract/3\">",
"      Wang PH, Chao HT, Yuan CC, et al. Ovarian tumors complicating pregnancy. Emergency and elective surgery. J Reprod Med 1999; 44:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4759/abstract/4\">",
"      Lee GS, Hur SY, Shin JC, et al. Elective vs. conservative management of ovarian tumors in pregnancy. Int J Gynaecol Obstet 2004; 85:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4759/abstract/5\">",
"      Leiserowitz GS. Managing ovarian masses during pregnancy. Obstet Gynecol Surv 2006; 61:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4759/abstract/6\">",
"      Dede M, Yenen MC, Yilmaz A, et al. Treatment of incidental adnexal masses at cesarean section: a retrospective study. Int J Gynecol Cancer 2007; 17:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4759/abstract/7\">",
"      Birchard KR, Brown MA, Hyslop WB, et al. MRI of acute abdominal and pelvic pain in pregnant patients. AJR Am J Roentgenol 2005; 184:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4759/abstract/8\">",
"      Gershenson DM, Silva EG, Levy L, et al. Ovarian serous borderline tumors with invasive peritoneal implants. Cancer 1998; 82:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4759/abstract/9\">",
"      Rajendran S, Hollingworth J, Scudamore I. Endodermal sinus tumour of the ovary in pregnancy. Eur J Gynaecol Oncol 1999; 20:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4759/abstract/10\">",
"      Mathevet P, Nessah K, Dargent D, Mellier G. Laparoscopic management of adnexal masses in pregnancy: a case series. Eur J Obstet Gynecol Reprod Biol 2003; 108:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4759/abstract/11\">",
"      Koo YJ, Kim HJ, Lim KT, et al. Laparotomy versus laparoscopy for the treatment of adnexal masses during pregnancy. Aust N Z J Obstet Gynaecol 2012; 52:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4759/abstract/12\">",
"      Candiani M, Maddalena S, Barbieri M, et al. Adnexal masses in pregnancy: fetomaternal blood flow indices during laparoscopic surgery. J Minim Invasive Gynecol 2012; 19:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4759/abstract/13\">",
"      Csapo AI, Pulkkinen MO, Ruttner B, et al. The significance of the human corpus luteum in pregnancy maintenance. I. Preliminary studies. Am J Obstet Gynecol 1972; 112:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4759/abstract/14\">",
"      Csapo AI, Pulkkinen MO, Wiest WG. Effects of luteectomy and progesterone replacement therapy in early pregnant patients. Am J Obstet Gynecol 1973; 115:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4759/abstract/15\">",
"      Egan PC, Costanza ME, Dodion P, et al. Doxorubicin and cisplatin excretion into human milk. Cancer Treat Rep 1985; 69:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4759/abstract/16\">",
"      American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108:776.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Acceptable medical reasons for use of breast-milk substitutes. WHO Press 2009. file://apps.who.int/iris/bitstream/10665/69938/1/WHO_FCH_CAH_09.01_eng.pdf (Accessed on November 26, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4759/abstract/18\">",
"      M&eacute;ndez LE, Mueller A, Salom E, Gonz&aacute;lez-Quintero VH. Paclitaxel and carboplatin chemotherapy administered during pregnancy for advanced epithelial ovarian cancer. Obstet Gynecol 2003; 102:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4759/abstract/19\">",
"      Picone O, Lhomm&eacute; C, Tournaire M, et al. Preservation of pregnancy in a patient with a stage IIIB ovarian epithelial carcinoma diagnosed at 22 weeks of gestation and treated with initial chemotherapy: case report and literature review. Gynecol Oncol 2004; 94:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4759/abstract/20\">",
"      Sood AK, Shahin MS, Sorosky JI. Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy. Gynecol Oncol 2001; 83:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4759/abstract/21\">",
"      Ferrandina G, Distefano M, Testa A, et al. Management of an advanced ovarian cancer at 15 weeks of gestation: case report and literature review. Gynecol Oncol 2005; 97:693.",
"     </a>",
"    </li>",
"    <li>",
"     NCCN Guidelines Version 1.2013. Epithelial Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer. National Comprehensive Cancer Network",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4759/abstract/23\">",
"      Zhao XY, Huang HF, Lian LJ, Lang JH. Ovarian cancer in pregnancy: a clinicopathologic analysis of 22 cases and review of the literature. Int J Gynecol Cancer 2006; 16:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4759/abstract/24\">",
"      Stensheim H, M&oslash;ller B, van Dijk T, Foss&aring; SD. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol 2009; 27:45.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3184 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-62E4DD783C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_41_4759=[""].join("\n");
var outline_f4_41_4759=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREOPERATIVE STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SURGICAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Management of corpus luteum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CHEMOTHERAPY AND TIMING OF DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREGNANCY TERMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      BREASTFEEDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      POSTOPERATIVE CARE AND FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3184\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3184|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/8/41099\" title=\"table 1\">",
"      Steps in staging ovarian cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/53/19287?source=related_link\">",
"      Chemotherapy of ovarian cancer in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9192?source=related_link\">",
"      Clinical manifestations and diagnosis of ovarian cancer in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=related_link\">",
"      Incidence and mortality of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8727?source=related_link\">",
"      Laparoscopic surgery in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15482?source=related_link\">",
"      Management of pregnant women undergoing nonobstetric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5128?source=related_link\">",
"      Ovarian tumors of low malignant potential",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7977?source=related_link\">",
"      Overview of fertility and pregnancy in cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=related_link\">",
"      Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=related_link\">",
"      Surgical management of advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33162?source=related_link\">",
"      Treatment of malignant germ cell tumors of the ovary",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_41_4760="Leuprolide: Drug information";
var content_f4_41_4760=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Leuprolide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/48/774?source=see_link\">",
"    see \"Leuprolide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/61/25558?source=see_link\">",
"    see \"Leuprolide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F187454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Eligard&reg;;",
"     </li>",
"     <li>",
"      Lupron Depot-Ped&reg;;",
"     </li>",
"     <li>",
"      Lupron Depot&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F187455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Eligard&reg;;",
"     </li>",
"     <li>",
"      Lupron&reg;;",
"     </li>",
"     <li>",
"      Lupron&reg; Depot&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F187474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Gonadotropin-Releasing Hormone Agonist;",
"     </li>",
"     <li>",
"      Gonadotropin Releasing Hormone Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F187456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Advanced prostate cancer:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Lupron Depot&reg; 7.5 mg (monthly):",
"     </i>",
"     7.5 mg every month",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Lupron Depot&reg; 22.5 mg (3 month):",
"     </i>",
"     22.5 mg every 12 weeks",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Lupron Depot&reg; 30 mg (4 month):",
"     </i>",
"     30 mg every 16 weeks",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Lupron Depot&reg; 45 mg (6 month):",
"     </i>",
"     45 mg every 24 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Eligard&reg;:",
"     </i>",
"     7.5 mg monthly",
"     <b>",
"      or",
"     </b>",
"     22.5 mg every 3 months",
"     <b>",
"      or",
"     </b>",
"     30 mg every 4 months",
"     <b>",
"      or",
"     </b>",
"     45 mg every 6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Leuprolide acetate 5 mg/mL solution:",
"     </i>",
"     1 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Endometriosis:",
"     </b>",
"     I.M.: Initial therapy may be with leuprolide alone or in combination with norethindrone; if retreatment for an additional 6 months is necessary, concomitant norethindrone should be used. Retreatment is not recommended for longer than one additional 6-month course.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Lupron Depot&reg;:",
"     </i>",
"     3.75 mg every month for up to 6 months",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Lupron Depot&reg;-3 month:",
"     </i>",
"     11.25 mg every 3 months for up to 2 doses (6 months total duration of treatment)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Uterine leiomyomata (fibroids):",
"     </b>",
"     I.M. (in combination with iron):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Lupron Depot&reg;:",
"     </i>",
"     3.75 mg every month for up to 3 months",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Lupron Depot&reg;-3 month:",
"     </i>",
"     11.25 mg as a single injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer, premenopausal ovarian ablation (unlabeled use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lupron Depot&reg;: 3.75 mg every 28 days for up to 24 months (Boccardo, 1999)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lupron Depot&reg;-3 month: 11.25 mg every 3 months for up to 24 months (Boccardo, 1999; Schmid, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of paraphilia/hypersexuality (unlabeled use; Guay, 2009; Reilly, 2000):",
"     </b>",
"     Males: I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     May cause an initial increase in androgen concentrations which may be treated with an antiandrogen (eg, flutamide, cyproterone) for 1-2 months (Guay, 2009). Avoid use in patients with osteoporosis or active pituitary pathology.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SubQ: Test dose: 1 mg (observe for hypersensitivity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depot I.M.: 3.75-7.5 mg monthly",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F187468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/61/25558?source=see_link\">",
"      see \"Leuprolide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Precocious puberty (consider discontinuing by age 11 for females and by age 12 for males):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M.:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Lupron Depot-Ped&reg; (monthly):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &le;25 kg: 7.5 mg every month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;25-37.5 kg: 11.25 mg every month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;37.5 kg: 15 mg every month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Titrate dose upward in increments of 3.75 mg every 4 weeks if down-regulation is not achieved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Lupron Depot-Ped&reg; (3 month): 11.25 mg or 30 mg every 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      SubQ (leuprolide acetate 5 mg/mL solution):",
"     </i>",
"     Initial: 50 mcg/kg/day; titrate dose upward by 10 mcg/kg/day if down-regulation is not achieved.",
"     <b>",
"      Note:",
"     </b>",
"     Higher mg/kg doses may be required in younger children.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F187457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16160287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16160288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F187429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as acetate [depot formulation, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Eligard&reg;: 7.5 mg (monthly), 22.5 mg (3 month), 30 mg (4 month), 45 mg (6 month) [contains polylactide-co-glycolide; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lupron Depot-Ped&reg;: 7.5 mg (monthly), 11.25 mg (3 month), 11.25 mg (monthly), 15 mg (monthly), 30 mg (3 month) [contains polylactide-co-glycolide, polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lupron Depot&reg;: 3.75 mg (monthly), 7.5 mg (monthly), 11.25 mg (3 month), 22.5 mg (3 month), 30 mg (4 month), 45 mg (6 month) [contains polylactide-co-glycolide, polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as acetate: 5 mg/mL (2.8 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F187414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Injection (solution)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F187433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Lupron Depot&reg;, Lupron Depot-Ped&reg;: Administer as a single injection. Vary injection site periodically",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Eligard&reg;: Vary injection site; choose site with adequate subcutaneous tissue (eg, upper or mid-abdomen, upper buttocks); avoid areas that may be compressed or rubbed (eg, belt or waistband)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Leuprolide acetate 5 mg/mL solution: Vary injection site; if an alternate syringe from the syringe provided is required, insulin syringes should be used",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F187432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Palliative treatment of advanced prostate cancer; management of endometriosis; treatment of anemia caused by uterine leiomyomata (fibroids); central precocious puberty",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F187470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of breast cancer; infertility; treatment of paraphilia/hypersexuality",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F187483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lupron Depot&reg; (1-month or 3-month formulation) may be confused with Lupron Depot-Ped&reg; (1-month or 3-month formulation)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lupron Depot-Ped&reg; is available in two formulations, a 1-month formulation and a 3-month formulation. Both formulations offer an 11.25 mg strength which may further add confusion.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F187472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Children",
"     </b>",
"     (percentages based on 1-month and 3-month pediatric formulations combined):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;10%: Local: Injection site pain (&le;20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cardiovascular: Vasodilation (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Central nervous system: Emotional lability (5%), mood altered (5%), headache (3% to 5%), pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dermatologic: Acne (3%), rash (3% including erythema multiforme), seborrhea (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Gastrointestinal: Weight gain (&le;7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Genitourinary: Vaginal bleeding (3%), vaginal discharge (3%), vaginitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Local: Injection site reaction (&le;9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Allergic reaction, alopecia, appetite decreased/increased, arthralgia, asthma, body odor, bradycardia, cervix disorder, constipation, cough, crying, depression, dizziness, dysmenorrhea, dyspepsia, dysphagia, epistaxis, extremity pain, feminization, fever, flu-like syndrome, gait disturbance, gingivitis, goiter, growth retarded, gynecomastia, hirsutism, hyperhidrosis, hyperkinesias, hypertension, infection, leukoderma, musculoskeletal pain, myalgia, myopathy, nausea, nervousness, obesity, pallor, peripheral edema, personality disorder, pharyngitis, purpura, rhinitis, sexual maturity accelerated, sinusitis, skin striae, somnolence, syncope, tearfulness, urinary incontinence, vision decreased, vomiting, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Adults:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     For prostate cancer treatment, an initial rise in serum testosterone concentrations may cause &ldquo;tumor flare&rdquo; or worsening of symptoms, including bone pain, neuropathy, hematuria, or ureteral or bladder outlet obstruction during the first 2 weeks. Similarly, an initial increase in estradiol levels, with a temporary worsening of symptoms, may occur in women treated with leuprolide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Delayed release formulations:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (&le;14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (&le;65%), pain (&lt;2% to 33%), depression (&le;31%), insomnia (&le;31%), fatigue (&le;17%), dizziness/vertigo (&le;16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Skin reaction (&le;12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes (25% to 98%), testicular atrophy (&le;20%), hyperlipidemia (&le;12%), libido decreased (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (&le;25%), bowel function altered (&le;14%), weight gain/loss (&le;13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginitis (11% to 28%), urinary disorder (13% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site burning/stinging (transient: &le;35%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (&le;18%), joint disorder (&le;12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (&le;12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10% (limited to important or life-threatening):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Angina (&lt;5%), arrhythmia (&lt;5%), atrial fibrillation (&lt;5%), bradycardia (&lt;5%), CHF (&lt;5%), deep thrombophlebitis (&lt;5%), hyper-/hypotension (&lt;5%), palpitation (&lt;5%), syncope (&lt;5%), tachycardia (&lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Nervousness (&le;8%), anxiety (&le;6%), confusion (&lt;5%), delusions (&lt;5%), dementia (&lt;5%), fever (&lt;5%), seizure (&lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne (&le;10%), alopecia (&le;5%), bruising (&le;5%), cellulitis (&lt;5%), pruritus (&le;3%), rash (&le;2%), hirsutism (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration (&le;8%), gynecomastia (&le;7%), breast tenderness/pain (&le;6%), bicarbonate decreased (&ge;5%), hyper-/hypocholesterolemia (&ge;5%), hyperglycemia (&ge;5%), hyperphosphatemia (&ge;5%), hyperuricemia (&ge;5%), hypoalbuminemia (&ge;5%), hypoproteinemia (&ge;5%), lactation (&lt;5%), testicular pain (&le;4%), menstrual disorder (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dysphagia (&lt;5%), gastrointestinal hemorrhage (&lt;5%), intestinal obstruction (&lt;5%), ulcer (&lt;5%), constipation (&le;3%), gastroenteritis/colitis (&le;3%), diarrhea (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Prostatic acid phosphatase increased/decreased (&ge;5%), urine specific gravity increased/decreased (&ge;5%), impotence (&le;5%), balanitis (&lt;5%), incontinence (&lt;5%), penile/testis disorder (&lt;5%), urinary tract infection (&lt;5%), nocturia (&le;4%), polyuria (2% to 4%), dysuria (&le;2%), bladder spasm (&lt;2%), erectile dysfunction (&lt;2%), hematuria (&lt;2%), urinary retention (&lt;2%), urinary urgency (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Eosinophilia (&ge;5%), leukopenia (&ge;5%), platelets increased (&ge;5%), anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver function tests abnormal (&ge;5%), partial thromboplastin time increased (&ge;5%), prothrombin time increased (&ge;5%), hepatomegaly (&lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site pain (2% to 5%), injection site erythema (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (&le;8%), paresthesia (&le;8%), neuropathy (&lt;5%), paralysis (&lt;5%), pathologic fracture (&lt;5%), bone pain (&lt;2%), arthralgia (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: BUN increased (&ge;5%), creatinine increased (&ge;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Emphysema (&lt;5%), epistaxis (&lt;5%), hemoptysis (&lt;5%), pleural effusion (&lt;5%), pulmonary edema (&lt;5%), dyspnea (&le;2%), cough (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (&le;5%), allergic reaction (&lt;5%), infection (5%), lymphadenopathy (&lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Immediate release formulation:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: ECG changes/ischemia (19%), peripheral edema (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pain (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes (55%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10% (limited to important or life-threatening):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (8%), murmur (3%), thrombosis/phlebitis (2%), CHF (1%), angina, arrhythmia, MI, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (7%), insomnia (7%), dizziness/lightheadedness (5%), anxiety, depression, fatigue, fever, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Dermatitis (5%), alopecia, bruising, itching, lesions, pigmentation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Gynecomastia/breast tenderness/pain (7%), testicular size decreased (7%), diabetes, hypercalcemia, hypoglycemia, libido decreased, thyroid enlarged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (7%), anorexia (6%), nausea/vomiting (5%), diarrhea, dysphagia, gastrointestinal bleeding, peptic ulcer, rectal polyps",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary frequency/urgency (6%), impotence (4%), urinary tract infection (3%), bladder spasm, dysuria, incontinence, testicular pain, urinary obstruction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (10%), bone pain (5%), peripheral neuropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Hematuria (6%), BUN increased, creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (2%), cough, pneumonia, pulmonary embolus, pulmonary fibrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection, inflammation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Children and Adults:",
"     </b>",
"     <i>",
"      Any formulations:",
"     </i>",
"     Postmarketing and/or case reports (Limited to important or life-threatening): Anaphylactic/anaphylactoid reactions, asthmatic reactions, bone density decreased, coronary artery disease, diabetes; fibromyalgia-like symptoms (arthralgia/myalgia, headaches, GI distress); hemoptysis, hepatic dysfunction, hypokalemia, hypoproteinemia, injection site induration/abscess, interstitial lung disease, liver injury, MI, pelvic fibrosis, penile swelling, peripheral neuropathy, photosensitivity; pituitary apoplexy (cardiovascular collapse, mental status altered, ophthalmoplegia, sudden headache, visual changes, vomiting); prostate pain, pulmonary embolism, pulmonary infiltrate, seizure, spinal fracture/paralysis, stroke, suicidal ideation/attempt (rare), tenosynovitis-like symptoms, thrombocytopenia, transient ischemic attack, uric acid increased, WBC decreased/increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F187436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to leuprolide, GnRH, GnRH-agonist analogs, or any component of the formulation; undiagnosed abnormal vaginal bleeding; pregnancy; breast-feeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lupron Depot&reg; 22.5 mg, 30 mg, and 45 mg are also not indicated for use in women",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F187418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abnormal menses: Females treated for precocious puberty may experience menses or spotting during the first 2 months of treatment; notify healthcare provider if bleeding continues after the second month.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Androgen-deprivation therapy (ADT) may increase the risk for cardiovascular disease (Levine, 2010). Sudden cardiac death and stroke have been reported in men receiving GnRH agonists. Long-term ADT may prolong the QT interval; consider the benefits of ADT versus the risk for QT prolongation in patients with a history of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, with medications known to prolong the QT interval, or with pre-existing cardiac disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Decreased bone density: Has been reported when used for &ge;6 months. Use caution in patients with additional risk factors for bone loss (eg, chronic alcohol use, corticosteroid therapy).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endometriosis: Exacerbation of endometriosis or uterine leiomyomata may occur initially.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperglycemia: Diabetes and/or worsening of glycemic control have been reported in men receiving GnRH agonists.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pituitary apoplexy: Rare cases of pituitary apoplexy (frequently secondary to pituitary adenoma) have been observed with GnRH agonist administration (onset from 1 hour to usually &lt;2 weeks); may present as sudden headache, vomiting, visual or mental status changes, and infrequently cardiovascular collapse; immediate medical attention required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Spinal cord compression: Has been reported when used for prostate cancer; closely observe patients for weakness and paresthesias in first few weeks of therapy. Observe patients with metastatic vertebral lesions closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor flare: Transient increases in testosterone (~50% above baseline) can lead to tumor flare, bone pain, hematuria, bladder outlet obstruction and neuropathy in prostate cancer patients during the first few weeks of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Urinary tract obstruction: Has been reported when used for prostate cancer; closely observe patients for urinary tract obstruction and hematuria in first few weeks of therapy. Observe patients with urinary obstruction closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostate cancer: Androgen deprivation therapy may increase the risk for cardiovascular disease, diabetes, insulin resistance, obesity, alterations in lipids, and fractures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric illness: Use with caution in patients with a history of psychiatric illness; alteration in mood, memory impairment, and depression have been associated with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Some dosage forms may contain benzyl alcohol which has been associated with &ldquo;gasping syndrome&rdquo; in neonates. Patients with benzyl alcohol allergy may demonstrate a hypersensitivity reaction (usually local) in the form of erythema and induration at the injection site.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depot formulations: Vehicle used in injectable (polylactide-co-glycolide microspheres) has rarely been associated with retinal artery occlusion in patients with abnormal arteriovenous anastomosis (eg, patent foramen ovale). Due to different release properties, combinations of dosage forms or fractions of dosage forms should not be interchanged.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6004203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Luteinizing Hormone-Releasing Hormone Analogs may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F187425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F187440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pregnancy must be excluded prior to the start of treatment. Although leuprolide usually inhibits ovulation and stops menstruation, contraception is not ensured and a nonhormonal contraceptive should be used. Fetal abnormalities and increased fetal mortality have been noted in animal studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F187462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F187439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Eligard Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (1): $493.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     22.5 mg (1): $1479.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (1): $1972.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     45 mg (1): $2959.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Lupron Depot Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.75 mg (1): $962.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (1): $1146.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     11.25 mg (1): $2886.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     22.5 mg (1): $3439.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (1): $4585.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     45 mg (1): $6879.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Lupron Depot-Ped Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (1): $1157.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     11.25 mg (1): $2101.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     11.25 mg (ped) (1): $6303.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (1): $2314.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (ped) (1): $6942.97",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F187427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bone mineral density",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Precocious puberty: GnRH testing (blood LH and FSH levels), measurement of height and bone age every 6-12 months, testosterone in males and estradiol in females (I.M. [monthly] and SubQ formulations: 1-2 months after initiation of therapy or with dosage change; I.M. [3 month] formulation: 2-3 months after initiation of therapy, month 6, and as clinically indicated thereafter); Tanner staging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prostatic cancer: LH and FSH levels, serum testosterone (~4 weeks after initiation of therapy), PSA; weakness, paresthesias, and urinary tract obstruction in first few weeks of therapy. Screen for diabetes (blood glucose and Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     ) and cardiovascular risk prior to initiating and periodically during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of paraphilia/hypersexuality (unlabeled use; Reilly, 2000): CBC (baseline, monthly for 4 months then every 6 months); serum testosterone (baseline, monthly for 4 months then every 6 months); serum LH (baseline and every 6 months), FSH (baseline), serum BUN and creatinine (baseline and every 6 months); bone density (baseline and yearly); ECG (baseline)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F187441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Eligard (AU, BG, DE, EE, FR, NZ);",
"     </li>",
"     <li>",
"      Enanton Depot (DK, FI, NO, SE);",
"     </li>",
"     <li>",
"      Enantone (AT, CL, DE, FR);",
"     </li>",
"     <li>",
"      Enantone Depot (IT);",
"     </li>",
"     <li>",
"      Enantone LP (TH);",
"     </li>",
"     <li>",
"      Enantone SR (HK);",
"     </li>",
"     <li>",
"      Endrolin (ID);",
"     </li>",
"     <li>",
"      Leuplin (KP);",
"     </li>",
"     <li>",
"      Leuplin Depot (TW);",
"     </li>",
"     <li>",
"      Lorelin (MX, PK);",
"     </li>",
"     <li>",
"      Lucrin (AU, MY, NZ, RU, SG, TR);",
"     </li>",
"     <li>",
"      Lucrin Depot (BE, CH, CR, CZ, GT, HN, IL, KP, MX, NI, NZ, PA, PL, SG, SV, TR);",
"     </li>",
"     <li>",
"      Lucrin PDS (MY);",
"     </li>",
"     <li>",
"      Luphere Depot (PH);",
"     </li>",
"     <li>",
"      Lupride (IN);",
"     </li>",
"     <li>",
"      Lupride Depot (IN);",
"     </li>",
"     <li>",
"      Lupro (TW);",
"     </li>",
"     <li>",
"      Luprolex (PH);",
"     </li>",
"     <li>",
"      Luprolex Depot (PH);",
"     </li>",
"     <li>",
"      Lupron (AR, BB, BM, BR, BS, CN, CO, EC, GY, JM, NL, PR, PY, SR, TT, UY, VE);",
"     </li>",
"     <li>",
"      Lupron Depot (AR, BR, CN, EC, PE, PY, UY, VE);",
"     </li>",
"     <li>",
"      Lupron SC (CO, PE);",
"     </li>",
"     <li>",
"      Prelar Depot (MX);",
"     </li>",
"     <li>",
"      Procren Depot (DK, FI, NO, SE);",
"     </li>",
"     <li>",
"      Procrin (ES);",
"     </li>",
"     <li>",
"      Prostap (GB, IE);",
"     </li>",
"     <li>",
"      Tapros (ID);",
"     </li>",
"     <li>",
"      Tapros 3M (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F187417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Leuprolide, is an agonist of luteinizing hormone-releasing hormone (LHRH). Acting as a potent inhibitor of gonadotropin secretion; continuous administration results in suppression of ovarian and testicular steroidogenesis due to decreased levels of LH and FSH with subsequent decrease in testosterone (male) and estrogen (female) levels. In males, testosterone levels are reduced to below castrate levels. Leuprolide may also have a direct inhibitory effect on the testes, and act by a different mechanism not directly related to reduction in serum testosterone.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F187435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Following transient increase, testosterone suppression occurs in ~2-4 weeks of continued therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Males: V",
"     <sub>",
"      d",
"     </sub>",
"     : 27 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 43% to 49%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Major metabolite, pentapeptide (M-1)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: SubQ: 94%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;5% as parent and major metabolite)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adjuvant Breast Cancer Trials Collaborative Group, &ldquo;Ovarian Ablation or Suppression in Premenopausal Early Breast Cancer: Results From the International Adjuvant Breast Cancer Ovarian Ablation or Suppression Randomized Trial,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2007, 99(7):516-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/41/4760/abstract-text/17405996/pubmed\" id=\"17405996\" target=\"_blank\">",
"        17405996",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boccardo F, Rubagotti A, Amoroso D, et al, &ldquo;Endocrinological and Clinical Evaluation of Two Depot Formulations of Leuprolide Acetate in Pre- and Perimenopausal Breast Cancer Patients,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 1999, 43(6):461-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/41/4760/abstract-text/10321505/pubmed\" id=\"10321505\" target=\"_blank\">",
"        10321505",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crawford ED, Eisenberger MA, McLeod DG, et al, &ldquo;A Controlled Trial of Leuprolide With and Without Flutamide in Prostatic Carcinoma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1989, 321(7):419-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/41/4760/abstract-text/2503724/pubmed\" id=\"2503724\" target=\"_blank\">",
"        2503724",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guay DR, &ldquo;Drug Treatment of Paraphilic and Nonparaphilic Sexual Disorders,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2009, 31(1):1-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/41/4760/abstract-text/19243704/pubmed\" id=\"19243704\" target=\"_blank\">",
"        19243704",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kappy MS, Stuart T, and Perelman A, &ldquo;Efficacy of Leuprolide Therapy in Children With Central Precocious Puberty,&rdquo;",
"      <i>",
"       Am J Dis Child",
"      </i>",
"      , 1988, 142(10):1061-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/41/4760/abstract-text/3140654/pubmed\" id=\"3140654\" target=\"_blank\">",
"        3140654",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keating NL, O&rsquo;Malley AJ, and Smith MR, &ldquo;Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(27):4448-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/41/4760/abstract-text/16983113/pubmed\" id=\"16983113\" target=\"_blank\">",
"        16983113",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krueger RB and Kaplan MS, &ldquo;Depot-Leuprolide Acetate for Treatment of Paraphilias: A Report of Twelve Cases,&rdquo;",
"      <i>",
"       Arch Sex Behav",
"      </i>",
"      , 2001, 30(4):409-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/41/4760/abstract-text/11446201/pubmed\" id=\"11446201\" target=\"_blank\">",
"        11446201",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee PA and Page JG, &ldquo;Effects of Leuprolide in the Treatment of Central Precocious Puberty,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1989, 114(2):321-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/41/4760/abstract-text/2492599/pubmed\" id=\"2492599\" target=\"_blank\">",
"        2492599",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee SJ, Schover LR, Partridge AH, et al, \"American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(18):2917-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/41/4760/abstract-text/16651642/pubmed\" id=\"16651642\" target=\"_blank\">",
"        16651642",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, D&rsquo;Amico AV, Berger P, et al, &ldquo;Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk. A Science Advisory from the American Heart Association, American Cancer Society, and American Urological Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 121:831-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/41/4760/abstract-text/20124128/pubmed\" id=\"20124128\" target=\"_blank\">",
"        20124128",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Loblaw DA, Virgo KS, Nam R, et al, &ldquo;Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2006 Update of an American Society of Clinical Oncology Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(12):1596-605.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/41/4760/abstract-text/17404365/pubmed\" id=\"17404365\" target=\"_blank\">",
"        17404365",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Metzger ML, Meacham LR, Patterson B, et al, \"Female Reproductive Health After Childhood, Adolescent, and Young Adult Cancers: Guidelines for the Assessment and Management of Female Reproductive Complications,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      2013, 31(9):1239-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/41/4760/abstract-text/23382474/pubmed\" id=\"23382474\" target=\"_blank\">",
"        23382474",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Plosker GL and Brogden RN, &ldquo;Leuprorelin. A Review of Its Pharmacology and Therapeutic Use in Prostate Cancer, Endometriosis and Other Sex Hormone-Related Disorders,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1994, 48(6):930-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/41/4760/abstract-text/7533699/pubmed\" id=\"7533699\" target=\"_blank\">",
"        7533699",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reilly DR, Delva NJ, and Hudson RW, &ldquo;Protocols for the Use of Cyproterone, Medroxyprogesterone, and Leuprolide in the Treatment of Paraphilia,&rdquo;",
"      <i>",
"       Can J Psychiatry",
"      </i>",
"      , 2000, 45(6):559-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/41/4760/abstract-text/10986575/pubmed\" id=\"10986575\" target=\"_blank\">",
"        10986575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schmid P, Untch M, Koss&eacute; V, et al, &ldquo;Leuprorelin Acetate Every-3-Months Depot versus Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Treatment in Premenopausal Patients With Node-Positive Breast Cancer: the TABLE Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(18):2509-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/41/4760/abstract-text/17577027/pubmed\" id=\"17577027\" target=\"_blank\">",
"        17577027",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schmid P, Untch M, Wallwiener D, et al, &ldquo;Cyclophosphamide, Methotrexate and Fluorouracil (CMF) Versus Hormonal Ablation With Leuprorelin Acetate as Adjuvant Treatment of Node-Positive, Premenopausal Breast Cancer Patients: Preliminary Results of the TABLE-Study (Takeda Adjuvant Breast Cancer Study With Leuprorelin Acetate),&rdquo;",
"      <i>",
"       Anticancer Res",
"      </i>",
"      , 2002, 22(4):2325-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/41/4760/abstract-text/12174922/pubmed\" id=\"12174922\" target=\"_blank\">",
"        12174922",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spry NA, Galv&atilde;o DA, Davies R, et al, &ldquo;Long-Term Effects of Intermittent Androgen Suppression on Testosterone Recovery and Bone Mineral Density: Results of a 33-Month Observational Study,&rdquo;",
"      <i>",
"       BJU Int",
"      </i>",
"      , 2009, 104(6):806-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/41/4760/abstract-text/19281463/pubmed\" id=\"19281463\" target=\"_blank\">",
"        19281463",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tanaka T, Niimi H, Matsuo N, et al, &ldquo;Results of Long-Term Follow-Up After Treatment of Central Precocious Puberty With Leuprorelin Acetate: Evaluation of Effectiveness of Treatment and Recovery of Gonadal Function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2005, 90(3):1371-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/41/4760/abstract-text/15598675/pubmed\" id=\"15598675\" target=\"_blank\">",
"        15598675",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tang J, and Weiter JJ, &ldquo;Branch Retinal Artery Occlusion After Injection of a Long-Acting Risperidone Preparation,&rdquo;",
"      <i>",
"       Annals Intern Med",
"      </i>",
"      , 2007, 147(4): 283-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/41/4760/abstract-text/17709768/pubmed\" id=\"17709768\" target=\"_blank\">",
"        17709768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thibaut F, De La Barra F, Gordon H, et al, &ldquo;The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Paraphilias,&rdquo;",
"      <i>",
"       World J Biol Psychiatry",
"      </i>",
"      , 2010, 11(4):604-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/41/4760/abstract-text/20459370/pubmed\" id=\"20459370\" target=\"_blank\">",
"        20459370",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9549 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-259ED97FEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_41_4760=[""].join("\n");
var outline_f4_41_4760=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187454\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187455\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187474\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187456\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187468\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187457\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160287\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160288\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187429\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187414\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187433\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187432\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187470\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187483\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187472\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187436\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187418\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299584\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6004203\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187425\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187440\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187462\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187439\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187427\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187441\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187417\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187435\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9549\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9549|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/48/774?source=related_link\">",
"      Leuprolide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/61/25558?source=related_link\">",
"      Leuprolide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_41_4761="Mild diverticulitis CT";
var content_f4_41_4761=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80808%7EGAST%2F76759%7EGAST%2F75134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80808%7EGAST%2F76759%7EGAST%2F75134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diverticulitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 344px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    41-year-old man with acute diverticulitis of sigmoid colon. Axial CT scan obtained with colonic contrast material and 5-mm collimation shows inflammatory wall thickening (straight arrow) and fat stranding (curved arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Kircher MF, Rhea JT, Kihiczak D, Novelline RA. Frequency, Sensitivity, and Specificity of Individual Signs of Diverticulitis on Thin- Section Helical CT with Colonic Contrast Material. AJR Am J Roentgenol 2002; 178:1313. Reprinted with permission from the American Journal of Roentgenology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diverticulitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 315px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    68-year old man with acute diverticulitis of sigmoid colon. Axial CT scans obtained with colonic contrast material and 5 mm collimation show asymmetric inflammatory wall thickening (curved arrow) superimposed on muscular wall hypertrophy (black arrow), diverticula, fat stranding, and fascial thickening (thin white arrow). Note contained perforation with formation of phlegmon and extraluminal air (thick white arrow). No free intraperitoneal extravasation of colonic contrast material is seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Kircher MF, Rhea JT, Kihiczak D, Novelline RA. Frequency, Sensitivity, and Specificity of Individual Signs of Diverticulitis on Thin- Section Helical CT with Colonic Contrast Material. AJR Am J Roentgenol 2002; 178:1313. Reprinted with permission from the American Journal of Roentgenology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diverticular abscess of the sigmoid colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Single axial CT scan of the pelvis demonstrates an abscess surrounding and compressing the sigmoid colon (large arrow) which is markedly narrowed. There is a small amount of gas within the abscess (arrowhead).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Norman Joffe, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_41_4761=[""].join("\n");
var outline_f4_41_4761=null;
var title_f4_41_4762="Free-living amebas";
var content_f4_41_4762=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Free-living amebas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/41/4762/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/41/4762/contributors\">",
"     Carlos Seas, MD, FIDSA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/41/4762/contributors\">",
"     Francisco Bravo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/41/4762/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/41/4762/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/41/4762/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/41/4762/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/41/4762/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H13571641\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Free-living amebas are environmental protozoan parasites with worldwide distribution. They exist in nature without the need for a host; they are not well adapted to parasitism and do not require a vector for transmission to humans or animals [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/1\">",
"     1",
"    </a>",
"    ]. Four genera cause disease in humans: Naegleria (only",
"    <em>",
"     N. fowleri",
"    </em>",
"    ), Acanthamoeba (several species), Balamuthia (only",
"    <em>",
"     B. mandrillaris",
"    </em>",
"    ), and Sappinia (only",
"    <em>",
"     S. pedata",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. All of these species cause central nervous system (CNS) infections, but several species of Acanthamoeba may cause localized extra-CNS infections in immunocompetent hosts or disseminated infections in immunocompromised hosts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571648\">",
"    <span class=\"h1\">",
"     CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two distinctive clinical syndromes associated with free-living amebas are well recognized: primary amebic meningoencephalitis (PAM) and granulomatous amebic encephalitis (GAE).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571655\">",
"    <span class=\"h2\">",
"     Primary amebic meningoencephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;PAM is an acute hemorrhagic meningoencephalitis caused by",
"    <em>",
"     N. fowleri.",
"    </em>",
"    It",
"    <em>",
"    </em>",
"    is characterized by a fulminant course with clinical and laboratory features that resemble acute bacterial meningitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571662\">",
"    <span class=\"h3\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     N. fowleri",
"    </em>",
"    is a thermophilic ameboflagellate protozoan parasite globally distributed in water and soil that lives in temperatures above 30&deg;C and tolerates temperatures up to 45&deg;C. The life cycle of",
"    <em>",
"     N. fowleri",
"    </em>",
"    includes three stages: the infective trophozoite, a transient non-dividing flagellate stage, and the cystic stage (",
"    <a class=\"graphic graphic_figure graphicRef53111 \" href=\"UTD.htm?27/4/27719\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <em>",
"     N. fowleri",
"    </em>",
"    has been isolated from a variety of fresh and warm water sources worldwide (lakes, ponds, rivers, streams, irrigation canals, hot springs, unchlorinated swimming pools, spas, aquaria, and sewage), but not from seawater [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. History of recreational water activities is the most common risk factor for infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/1\">",
"     1",
"    </a>",
"    ]. Activities such as swimming, diving, jumping, splashing, use of watercrafts, waterskiing, surfing, exposure to hot springs, and facial contact with mud have been reported in PAM cases. Isolation of the ameba in the environment where cases have occurred is common [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/6\">",
"     6",
"    </a>",
"    ]. Tap water exposures during ritual purification and nasal irrigation have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Asymptomatic children and patients with PAM may harbor the ameba in the nasal mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/9\">",
"     9",
"    </a>",
"    ]. There is concern that global warming and changes in the ecosystems",
"    <em>",
"     N. fowleri",
"    </em>",
"    inhabit may lead to more cases worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/7,10\">",
"     7,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PAM was initially reported in Australia in 1965; since then, it has been reported in more than 16 countries [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/11\">",
"     11",
"    </a>",
"    ]. The total number of cases is unknown; it is estimated that approximately 300 cases have occurred worldwide. The largest series of well-documented PAM cases comes from the United States, in which 111 PAM cases were reported. The mean patient age was 12 years (range 8 months to 66 years); 79 percent were males and 62 percent were children. No evidence of immunosuppression was identified, and 87 percent of cases occurred during the summer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/11\">",
"     11",
"    </a>",
"    ]. Water exposure occurred in 81 percent of cases, including exposure to lakes and ponds in 74 percent. No clear source was identified in 19 percent of cases.",
"   </p>",
"   <p>",
"    Exposure is more common than disease. There is a high prevalence of positive serology [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], while the risk of infection is approximately 2.6 cases per million exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/14\">",
"     14",
"    </a>",
"    ]. The reasons for the low prevalence of disease in humans despite frequent exposure are unknown.",
"   </p>",
"   <p>",
"    Transmission to humans occurs primarily through inhalation of infested water. Activities that increase contact of the nasal mucosa with infested water predispose humans to infection. Trophozoites penetrate the olfactory mucosa, cross the cribriform plates, and ultimately reach the olfactory bulb. Water exposure in patients with tympanic membrane ruptures may also lead to PAM [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/15\">",
"     15",
"    </a>",
"    ]. Cases of infection with no clear history of exposure have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571669\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;PAM is an acute meningoencephalitis associated with an extremely high mortality rate. The case fatality rate in the largest well-documented series was 99 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/11\">",
"     11",
"    </a>",
"    ]. In that study the mean incubation period was 5 days (range 1 to 7 days), the mean hospital stay was 3.2 days (range 0 to 11 days), the mean time from onset of symptoms to death was 5.3 days (range 1 to 12 days), and the mean time from exposure to death was 9.9 days (range 6 to 17 days).",
"   </p>",
"   <p>",
"    Common clinical manifestations include high fever, severe headache, photophobia, nausea, vomiting, behavioral abnormalities, seizures, and altered mental status. Smell and taste abnormalities may occur early and may reflect the migration of the organism through the olfactory mucosa. Physical examination demonstrates meningeal signs (Kerning and Brudzinski signs) and cranial nerve palsies indicating uncal herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/2\">",
"     2",
"    </a>",
"    ]. The progression of the disease is very rapid, with profound mental alteration and severe cranial hypertension leading to herniation and death in a matter of few days. Cardiac involvement with arrhythmia has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory findings demonstrate leukocytosis with neutrophilia. Examination of the cerebral spinal fluid (CSF) demonstrates a yellowish-white to grayish color initially, which turns into frankly hemorrhagic fluid as the disease progresses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/2\">",
"     2",
"    </a>",
"    ]. The CSF white blood cell count ranges from 300 to 26,000 cells per mm",
"    <sup>",
"     3",
"    </sup>",
"    with marked polymorphonuclear predominance; CSF red blood cells are usually seen, ranging from 250 to 24,600 cells per mm",
"    <sup>",
"     3",
"    </sup>",
"    . Glucose is usually markedly consumed in the CSF, and the protein concentration is usually elevated. CSF pressure is usually very high, ranging from 300 to 600 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/2\">",
"     2",
"    </a>",
"    ]. Studies for bacterial pathogens are usually negative, including Gram stain and culture. However, secondary bacterial infections can be introduced by the ameba; this was illustrated in a report of",
"    <em>",
"     Burkholderia cepacia",
"    </em>",
"    (a soil-water transmitted pathogen) infection of the CSF in a patient with PAM [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571676\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should have a high index of suspicion when encountering patients with acute meningoencephalitis with negative results for bacteria and common viruses, which should prompt the search for amebas in the CSF. History of exposure increases the likelihood of PAM, but it is not always obtained.",
"   </p>",
"   <p>",
"    The diagnosis of PAM is generally established via observation of motile trophozoites on examination of a centrifuged CSF wet mount preparation immediately after obtaining the sample. A phase contrast microscope is useful to optimize visualization of the ameba. Trophozoites tend to immobilize when exposed to diluted fluid and may resemble leukocytes. Giemsa or trichrome stains help in identifying morphologic features of the trophozoites: 10 to 25 microns in size with a single nucleus and a centrally located nucleolus with no peripheral chromatin (",
"    <a class=\"graphic graphic_picture graphicRef87778 \" href=\"UTD.htm?7/3/7222\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef58751 \" href=\"UTD.htm?16/1/16404\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multiplex polymerase chain reaction (PCR) facilitates for rapid detection; it can identify the DNA of the major free-living amebas in CSF in about five hours, although this diagnostic methodology is not widely available [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/16\">",
"     16",
"    </a>",
"    ].",
"    <em>",
"     N. fowleri",
"    </em>",
"    can be isolated in non-nutrient agar coated with enteric bacteria. Serology is not useful for diagnosis.",
"   </p>",
"   <p>",
"    Imaging findings on computed tomography (CT) and magnetic resonance imaging (MRI) are nonspecific. Brain edema, basilar meningeal enhancement, hydrocephalus, and areas of cerebral infarction have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/17\">",
"     17",
"    </a>",
"    ]. Lesions in the brain tend to be located in the orbito-frontal and temporal lobes, base of the brain, cerebellum, and upper spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/18\">",
"     18",
"    </a>",
"    ]. A purulent exudative inflammation along the leptomeninges and extensive necrosis and hemorrhage of the parenchyma are characteristic pathological findings (",
"    <a class=\"graphic graphic_picture graphicRef87780 \" href=\"UTD.htm?42/26/43431\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Brain tissue can be examined for trophozoites, and brain sections can be stained with immunofluorescent anti-",
"    <em>",
"     N. fowleri",
"    </em>",
"    antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571683\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach to treatment is uncertain; no studies evaluating the efficacy of single drug or combination drug regimens have been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/21\">",
"     21",
"    </a>",
"    ]. We favor initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    as soon as the diagnosis is considered; empiric initiation of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    and oral rifampicin is also appropriate.",
"   </p>",
"   <p>",
"    The rarity of the disease, delay in diagnosis, fulminant clinical course, and the difficulties in making a rapid diagnosis have hampered the evaluation of drug regimens. In theory, the best drug regimen should include an amebicidal drug (or a combination of drugs) with good in vitro activity that is capable of crossing the blood brain barrier.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    deoxycholate demonstrates the most favorable in vitro activity (with minimal inhibitory concentrations [MICs] in the range of 0.026 to 0.078",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    and is considered the drug of choice. Administration of amphotericin B (1.5",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    is warranted as soon as the diagnosis is considered [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/22\">",
"     22",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     Liposomal amphotericin B",
"    </a>",
"    is less nephrotoxic, but is less effective in animal models and has higher MICs than the conventional preparation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other in vitro active drugs include the azoles (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , miconazole,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ), rifampicin, miltefosine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/4\">",
"     4",
"    </a>",
"    ]. The in vitro activity of rifampicin is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/25\">",
"     25",
"    </a>",
"    ]. Variations in virulence factors and sensitivity to antimicrobials have been postulated to explain clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 11 survivors of PAM are reported in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/7,21,26-28\">",
"     7,21,26-28",
"    </a>",
"    ]. In most of these cases, an early diagnosis was made and treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    was initiated promptly; the most frequently used regimen was amphotericin B plus rifampicin (10",
"    <span class=\"nowrap\">",
"     mg/kg/day).",
"    </span>",
"    Synergy of amphotericin B with azoles (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    10",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    has also been described. In one case, intrathecal administration of amphotericin B and miconazole was used [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571690\">",
"    <span class=\"h2\">",
"     Granulomatous amebic encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomatous amebic encephalitis (GAE) is a rare subacute-chronic infection of the CNS caused by Acanthamoeba species,",
"    <em>",
"     B. mandrillaris,",
"    </em>",
"    and",
"    <em>",
"     S. pedata",
"    </em>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571697\">",
"    <span class=\"h3\">",
"     Acanthamoeba",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acanthamoeba is the most common ameba found in nature and largely causes opportunistic infections in immunocompromised hosts. Predisposing conditions include diabetes, alcoholism, cirrhosis, HIV infection, chronic renal failure, systemic lupus, malignancy, chemotherapy, and organ transplantation including hematopoietic stem cell transplantation (mostly allogenic transplant recipients) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/29\">",
"     29",
"    </a>",
"    ]. Of more than 150 cases of GAE reported in the literature, 11 have been in immunocompetent hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571704\">",
"    <span class=\"h4\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acanthamoeba can be found in soil (beach sands, flower pot soil), air, and in a number of water environments rich in biofilms (brackish water, sewage, humidifiers, heating hospital environments, dental and dialysis units, contact lenses) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/5\">",
"     5",
"    </a>",
"    ]. Modes of transmission include inhalation of cysts carried by wind through the respiratory tract or direct skin contact followed by hematogenous spread [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/1\">",
"     1",
"    </a>",
"    ]. No seasonality has been reported, and usually no history of water or soil exposure is elicited from GAE patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/4\">",
"     4",
"    </a>",
"    ]. Acanthamoeba have been found in the nasal mucosa of both patients and asymptomatic individuals, suggesting a nasal route of spread [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The acanthamoeba life cycle includes two stages: a vegetative trophozoite and a cyst (",
"    <a class=\"graphic graphic_figure graphicRef70542 \" href=\"UTD.htm?12/55/13174\">",
"     figure 2",
"    </a>",
"    ). Seventeen different genotypes have been identified, from T1 to T17; the majority of human cases are associated with the genotype T4, followed by genotypes T1, T10, and T12 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/30\">",
"     30",
"    </a>",
"    ]. A unique case associated with genotype T2 in an HIV-infected patient has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other infections can occur simultaneously with Acanthamoeba, including",
"    <em>",
"     Legionella",
"    </em>",
"    spp,",
"    <em>",
"     Vibrio cholerae",
"    </em>",
"    ,",
"    <em>",
"     Burkholderia cepacia",
"    </em>",
"    ,",
"    <em>",
"     Listeria",
"    </em>",
"    <em>",
"     monocytogenes",
"    </em>",
"    , and",
"    <em>",
"     Mycobacterium",
"    </em>",
"    spp [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/5,32\">",
"     5,32",
"    </a>",
"    ]. A fatal case of multiple protozoan infections (Acanthamoeba spp,",
"    <em>",
"     Balamuthia mandrillaris",
"    </em>",
"    , and",
"    <em>",
"     Toxoplasma gondii",
"    </em>",
"    ) in an HIV-infected patient has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571711\">",
"    <span class=\"h4\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;GAE consists of a prolonged clinical course characterized by weeks or months of worsening headache, low-grade fever, visual disturbances, behavioral abnormalities, and focal neurologic deficits depending on the topographic location of lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/2\">",
"     2",
"    </a>",
"    ]. The incubation period is usually not known as it is often difficult to determine when exposure took place. As the disease progresses, intracranial pressure, seizures, loss of consciousness, comas, and ultimately death ensue.",
"   </p>",
"   <p>",
"    Lumbar puncture is generally contraindicated for patients who present with a focal lesion associated with elevated intracranial pressure. For patients in whom the CSF can be obtained, nonspecific findings are the rule, including mild pleocytosis with lymphocytic predominance, high protein concentration, and low or normal glucose concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/34\">",
"     34",
"    </a>",
"    ]. Acanthamoeba trophozoites are seldom seen in a CSF sample [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/1\">",
"     1",
"    </a>",
"    ], but Giemsa stain of the CSF sediment may demonstrate trophozoites [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571718\">",
"    <span class=\"h4\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consideration of GAE in the differential diagnosis of CNS space occupying lesions in immunocompromised hosts is imperative; failure to consider the diagnosis is an important reason that antemortem diagnosis is usually missed.",
"   </p>",
"   <p>",
"    Brain tissue is needed to confirm the diagnosis. Staining with hematoxylin-eosin demonstrates both trophozoites and cysts. Trophozoites are seen in the perivascular space; their size is 15 to 30 microns and they have a large nucleolus with a centrally-located nucleolus (",
"    <a class=\"graphic graphic_picture graphicRef64215 \" href=\"UTD.htm?24/25/24980\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/34\">",
"     34",
"    </a>",
"    ]. Thick-walled cysts (10 to 25 microns usually with a double layer) can be seen in tissue sections (",
"    <a class=\"graphic graphic_picture graphicRef87781 \" href=\"UTD.htm?1/38/1640\">",
"     picture 5",
"    </a>",
"    ). In patients with concomitant skin or pulmonary lesions, tissue samples from these organs may also demonstrate trophozoites [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/36\">",
"     36",
"    </a>",
"    ]. Indirect immunofluorescence and immunoperoxidase stains are helpful for identifying Acanthamoeba in brain and other tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/34,37\">",
"     34,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tissue samples can be cultured in non-nutrient agar coated by enteric bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/4\">",
"     4",
"    </a>",
"    ]. PCR methods applied to brain or other tissues provide a more rapid diagnosis; however, availability of these methods is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/16,38\">",
"     16,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Brain CT scans and magnetic resonance imaging show single or multiple space-occupying lesions with ring enhancement (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85823 \" href=\"UTD.htm?31/57/32662\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/39\">",
"     39",
"    </a>",
"    ]. Temporal and parietal lobes are most commonly affected.",
"   </p>",
"   <p>",
"    Postmortem examination of the brain demonstrates significant edema and multiple hemorrhagic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/4\">",
"     4",
"    </a>",
"    ]. Microscopic examination reveals extensive necrosis and the presence of multinucleated giant cells. Granulomas can be seen in immunocompetent patients, and an abundance of both trophozoites and cysts located in perivascular areas are characteristic findings (",
"    <a class=\"graphic graphic_picture graphicRef88021 \" href=\"UTD.htm?36/27/37300\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571725\">",
"    <span class=\"h4\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach to treatment is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/40\">",
"     40",
"    </a>",
"    ]; therefore, combination regimens are preferred over single drug regimens. We favor empiric treatment with a combination of miltefosine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    isethionate.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    , and a macrolide (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ) can be added to this regimen as well.",
"   </p>",
"   <p>",
"    A number of drugs have in vitro activity and have resulted in success for a few patients when used alone or in combination: rifampicin, azoles (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    isethionate,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , miltefosine, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/34,41-48\">",
"     34,41-48",
"    </a>",
"    ]. Variations in susceptibility and virulence may account for poor clinical responses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acanthamoeba are not inhibited in vitro by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/46\">",
"     46",
"    </a>",
"    ], although cure with amphotericin B plus rifampicin has been reported in one patient [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/49\">",
"     49",
"    </a>",
"    ]. Cure using miltefosine monotherapy has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/47\">",
"     47",
"    </a>",
"    ]. The benefit of hyperbaric oxygen is uncertain; its use in combination with pentamidine isethionate, miltefosine, fluconazole, trimethoprim-sulfamethoxazole, and metronidazole was successful in one patient [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Single cerebral lesions should be resected if possible [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571732\">",
"    <span class=\"h3\">",
"     Balamuthia mandrillaris",
"    </span>",
"    &nbsp;&mdash;&nbsp;The life cycle is summarized in the graphic (",
"    <a class=\"graphic graphic_figure graphicRef77004 \" href=\"UTD.htm?2/22/2406\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571739\">",
"    <span class=\"h4\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     B. mandrillaris",
"    </em>",
"    infection was initially isolated from the brain of a baboon that died of meningoencephalitis at the San Diego Zoo in 1986 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/51\">",
"     51",
"    </a>",
"    ]. A serologic test was developed from this isolate and subsequently used to establish a posthumous diagnosis for 16 human cases of meningoencephalitis due to an unknown ameba (including cases from the United States, Mexico, Peru, Venezuela, and Australia).",
"   </p>",
"   <p>",
"    The organism was further isolated and identified in 1993 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/52\">",
"     52",
"    </a>",
"    ]. Subsequently, about 200 cases have been reported from all continents except from Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. Most cases are reported in the western hemisphere, with the highest concentration in South America and the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/57-69\">",
"     57-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a 2011 review of 35 cases in the United States, most came from the southern states: 15 from California, 6 in Arizona, 6 in Texas, and 3 from Mississippi [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/53\">",
"     53",
"    </a>",
"    ]. Males were affected 2.5 times more frequently than females, and 55 percent of patients were younger than 15 years old. The disease appears to occur more frequently among patients of Hispanic origin; possible explanations include genetic susceptibility or environmental exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/53,70\">",
"     53,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Balamuthia is most commonly isolated from soil [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/71-74\">",
"     71-74",
"    </a>",
"    ]. Infection has been correlated with activities such as agricultural exposure, desert motorcycling, dirt biking, swimming, and gardening [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/53\">",
"     53",
"    </a>",
"    ]. The disease may occur in immunocompetent as well as in immunosuppressed patients, and transmission via organ donation has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571746\">",
"    <span class=\"h4\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two patterns of clinical presentation have been described: some patients develop an initial skin lesion followed by development of the neurologic manifestations in weeks or months, while others present with CNS involvement.",
"   </p>",
"   <p>",
"    Early recognition of the skin lesion may facilitate diagnosis and treatment prior to development of CNS involvement. In some cases, the skin lesion may disappear in the absence of treatment; in such circumstances, subsequent CNS involvement still develops.",
"   </p>",
"   <p>",
"    Patients with cutaneous involvement commonly present with a non-ulcerated asymptomatic plaque, either single or with occasional satellite lesions (",
"    <a class=\"graphic graphic_picture graphicRef88059 \" href=\"UTD.htm?13/5/13397\">",
"     picture 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/54,56,76,77\">",
"     54,56,76,77",
"    </a>",
"    ]. A history of previous trauma can be elicited in many cases. The most common location is the central face over the nose; other locations described are the knee, thigh, chest, and elbow. Occasionally the border is raised, giving the appearance of an annular lesion. The diameter may be one to several centimeters, and the color may vary from skin toned to slightly red with a violaceous hue. In some cases the border is ill-defined, suggesting soft tissue infiltration. If untreated, tissue infiltration may progress to involve the central face. Sensation is preserved, a sign that permits differentiation from tuberculoid leprosy.",
"   </p>",
"   <p>",
"    CNS symptoms are due to thrombotic angiitis, leading to hemorrhage, infarction, and necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/58\">",
"     58",
"    </a>",
"    ]. Patients who present with neurologic involvement commonly have fever and malaise [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/53\">",
"     53",
"    </a>",
"    ]. Initial symptoms may include regression, unilateral headaches, focal seizures, cranial nerve dysfunction, or localized motor deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/57,78\">",
"     57,78",
"    </a>",
"    ]. Signs of increased intracranial pressure (diffuse headache, nausea, and vomit) may be present, and later meningeal signs may develop, followed by progressive loss of consciousness (from stupor to coma). This progression generally occurs over 2 to 12 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571753\">",
"    <span class=\"h4\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognition of the characteristic skin lesion on the central face facilitates early treatment and potential cure of an otherwise fatal disease. The differential diagnosis for cutaneous lesions involving sites other than the face is broader, and a high index of suspicion is required. Common histopathologic characteristics include the presence of a diffuse granulomatous reaction on the reticular dermis in the absence of epidermal changes, ill-defined granulomas, surrounding infiltrate rich in lymphocytes and plasma cells, and abundant multinucleated giant cells inside and outside granulomas (",
"    <a class=\"graphic graphic_picture graphicRef87833 \" href=\"UTD.htm?37/22/38249\">",
"     picture 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/26\">",
"     26",
"    </a>",
"    ]. Definitive diagnosis requires visualization of a trophozoite; these are present in 60 to 75 percent of cases and are scarce in number. In addition, trophozoites may be easily confused with histiocytes; visualization of the nucleus and nucleolus of the amoeba may be a distinguishing clue.",
"   </p>",
"   <p>",
"    Direct immunofluorescence or immunoperoxidase staining should be performed if possible [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/52,79\">",
"     52,79",
"    </a>",
"    ]. These are species-specific assays with high sensitivity for detection of the ameba in tissue; they can be performed at the United States Centers for Disease Control and Prevention (CDC). A PCR technique for detection of amebic DNA material in human tissue has been developed based on a probe consisting of a primer-pair from sequence data of the Balamuthia mitochondrial 16S rRNA gene [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of CNS involvement, the diagnosis is much more challenging due to a broader differential diagnosis. Clinical clues include a hemorrhagic spinal tap and presence of subacute meningoencephalitis not responding to appropriate antibiotic therapy. CSF may demonstrate lymphocytic pleocytosis with mild to severe elevation of protein concentration and normal to low glucose concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/78\">",
"     78",
"    </a>",
"    ]. Balamuthia is rarely seen in the CSF. Real-time PCR on CSF can provide results in five hours, although this is not available in many areas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Imaging of CNS by CT or MRI typically demonstrates multiple lesions ranging from small, solid lesions to large, nodular lesions with ring enhancement (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87788 \" href=\"UTD.htm?2/63/3058\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/81\">",
"     81",
"    </a>",
"    ]. Intralesional hemorrhage is an important radiological clue.",
"   </p>",
"   <p>",
"    Brain biopsy typically demonstrates granulomas with foamy macrophages and multinucleated giant cells accompanied by lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/57,79\">",
"     57,79",
"    </a>",
"    ]. Amebae have a predilection for location in the vascular walls of capillaries and venules, and vascular damage may be present as tissue hemorrhage. Neutrophils may predominate and amebas may be seen. Direct immunofluorescence or immunoperoxidase staining should also be performed if possible, as with skin biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571760\">",
"    <span class=\"h4\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach to treatment is uncertain; experience is based on a limited number of case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/82-86\">",
"     82-86",
"    </a>",
"    ]. Treatment with multiple drugs for a prolonged duration is warranted.",
"   </p>",
"   <p>",
"    In the United States, six surviving patients have received a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    , 5-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    , and a macrolide (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ) plus any of the following:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    , miltefosine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"     thioridazine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/84-86\">",
"     84-86",
"    </a>",
"    ]. In Peru, five surviving patients have been treated with a combination of fluconazole or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , in addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    and miltefosine [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/82\">",
"     82",
"    </a>",
"    ]. Three patients had CNS involvement at the time of presentation, and two had cutaneous involvement only.",
"   </p>",
"   <p>",
"    Wide resection of the skin lesion has been used as an additional therapy in some Peruvian cases. A similar approach may be useful for patients with single CNS lesions, followed by medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571767\">",
"    <span class=\"h3\">",
"     Sappinia pedata",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genus Sappinia comprises two species,",
"    <em>",
"     S. pedata",
"    </em>",
"    and",
"    <em>",
"     S. diploidea",
"    </em>",
"    . The life cycle of these amebas involves a vegetative trophozoite and a cystic form; animal feces appear to be a necessary component of the life cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/87\">",
"     87",
"    </a>",
"    ]. A PCR assay can discriminate between the two species of Sappinia, and can be incorporated into already existing multiplex PCR methods to detect",
"    <em>",
"     Acanthamoeba",
"    </em>",
"    spp.,",
"    <em>",
"     B. mandrillaris,",
"    </em>",
"    and",
"    <em>",
"     N. fowleri",
"    </em>",
"    , allowing for rapid detection and prompt initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Only one human case of GAE due to Sappinia has been reported (attributed to",
"    <em>",
"     S. pedata",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/90\">",
"     90",
"    </a>",
"    ]. The patient was a previously healthy 38-year-old male farmer with no evidence of immunosuppression and engaged in handling livestock; he presented with headache, vomiting, loss of consciousness, and blurry vision following a sinus infection. A single 2-cm focal lesion located in the posterior left temporal lobe was found and resected. The pathological examination demonstrated trophozoites (40 to 60 microns in diameter) with two nuclei (",
"    <a class=\"graphic graphic_picture graphicRef54458 \" href=\"UTD.htm?3/62/4069\">",
"     picture 9",
"    </a>",
"    ). The infection was likely acquired by inhalation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patient was treated with a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (250",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 31 weeks), intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    isethionate (300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 6 weeks),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (200",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    and 5-fluorcystosine (2.75 g four times a day for 25 weeks) with complete recovery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571774\">",
"    <span class=\"h1\">",
"     INFECTIONS OUTSIDE THE CENTRAL NERVOUS SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acanthamoeba can cause infection outside of the central nervous system (CNS); these include localized infections involving the skin, the nasopharyngeal area, and keratitis. Disseminated infections have also been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571781\">",
"    <span class=\"h2\">",
"     Cutaneous infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acanthamoeba cutaneous infection is a rare clinical presentation seen mostly in immunocompromised hosts. It was initially described in an HIV-infected patient, but it has been associated with other immunosuppressive conditions; it has also been reported in healthy hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/44,91,92\">",
"     44,91,92",
"    </a>",
"    ]. The differential diagnosis is wide and includes viral, mycobacterial, fungal, and bacterial infections.",
"   </p>",
"   <p>",
"    One report of five culture-confirmed cases collected over 11 years in a single institution in Peru noted that 80 percent were male, the mean age was 28 years, the clinical course was prolonged (duration of symptoms of approximately 4 months), and fresh water exposure was noted in two cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/92\">",
"     92",
"    </a>",
"    ]. Three patients were HIV-infected, had only cutaneous involvement, and died of opportunistic infections; two patients had no evidence of immunosuppression and developed granulomatous amebic encephalitis (GAE) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/92\">",
"     92",
"    </a>",
"    ]. Cutaneous lesions began as papules or nodules mostly in the lower limbs and evolved to necrotic ulcers in four patients. Other lesions included infiltrative plaques and cellulitis-like lesions. Lesions may be painful or painless. Pathological examination demonstrated an intense inflammatory reaction in the dermis with histiocyte predominance. Plasmocytes and neutrophils were also present, and Acanthamoeba trophozoites were abundant [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal approach to treatment of localized cutaneous infections is uncertain. Regimens that have been tried with success include twice daily applications of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine gluconate",
"    </a>",
"    and 2 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    cream, combined with systemic therapy including intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    isethionate, an azole (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    or ketoconazole), and 5-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/44,93\">",
"     44,93",
"    </a>",
"    ]. Other successful combination regimens have included miltefosine, 5-fluorcytosine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/94\">",
"     94",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    plus voriconazole [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571788\">",
"    <span class=\"h2\">",
"     Nasopharyngeal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acanthamoeba infection of the nasal mucosa and paranasal sinuses is a very rare condition that has been described primarily in severely immunosuppressed HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/95\">",
"     95",
"    </a>",
"    ]. The disease is characterized by a chronic course with nasal discharge and sinusitis unresponsive to antimicrobials. Concomitant skin lesions are common [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/95\">",
"     95",
"    </a>",
"    ]. Findings on the physical examination include purulent nasal secretion, hard brown crusts, and erosion of the nasal septum. Computed tomography (CT) imaging demonstrates mucosal thickening. The diagnosis is established via tissue biopsy stained with hematoxylin-eosin demonstrating a large number of trophozoites.",
"   </p>",
"   <p>",
"    Medical treatment has been largely unsuccessful; few patients have responded. Management should consist of surgical excision combined with medical treatment. Drugs that have been administered successfully in one patient include 5-fluorcytosine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , rifampicin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571795\">",
"    <span class=\"h2\">",
"     Keratitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acanthamoeba may infect the cornea; keratitis usually occurs among immunocompetent contact lens wearers who do not adhere to proper cleaning procedures, or as a result of direct inoculation following trauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571802\">",
"    <span class=\"h3\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main risk factor for acquiring amebic keratitis is wearing contact lenses for long periods of time. Acanthamoeba has been isolated from contact lenses cases, from which it is seeded into the eye, penetrating the corneal stroma and establishing chronic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/21\">",
"     21",
"    </a>",
"    ]. Use of nonsterile tap water in preparation of contact lens solutions is a well recognized route of acquisition. In addition, contaminated commercial contact lens solutions have been associated with transmission in the United Kingdom and the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. Factors associated with amebic keratitis include use of recalled contact lens solutions, daily use of soft contact lenses, use of all-in-one lens solutions, showering while wearing contact lenses, and poor contact lens hygiene [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571809\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations include conjunctival hyperemia, tearing, foreign body sensation, pain, and photophobia. Usually a single eye is affected, but bilateral involvement has been observed. Epithelial irregularities and pseudodendritic epithelial lesions are considered early lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/100\">",
"     100",
"    </a>",
"    ]. Ring-shaped stromal infiltrates are characteristic late stage lesions of Acanthamoeba keratitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571816\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trophozoites can be visualized via staining of cornea scrapings with fluorescent dye calcofluor [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/101\">",
"     101",
"    </a>",
"    ]. Cornea scrapings can be cultured and molecular methods can be applied to differentiate species and quantify the amebic load. In general, PCR methods are more sensitive than special stains and cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/102\">",
"     102",
"    </a>",
"    ]. Corneal biopsies can be cultured and examined microscopically for the presence of trophozoites and cysts. Four genotypes are responsible for most of the infections (T4, T3, T6, and T11) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571823\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment should be instituted promptly, although the optimal approach is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/21\">",
"     21",
"    </a>",
"    ]; prolonged infection is a recognized factor for treatment failure. Combination therapy should be administered, including polyhexamethylene biguanide (0.02 percent PHMB), or biguanide-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    in combination with propamidine (0.1 percent) or hexamidine (0.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]. Initially, drops should be applied frequently, with subsequent taper over three to four weeks. Debridement may also be warranted.",
"   </p>",
"   <p>",
"    Challenges in treatment of Acanthamoeba keratitis include ameba encystation and development of resistance to medication. Prognostic factors for achieving best visual acuity response include good initial visual acuity, infection related to swimming, absence of epithelial defect, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    , and no receipt of steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic refractory cases may require corneal transplantation. Unresponsive cases may require enucleation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571830\">",
"    <span class=\"h2\">",
"     Disseminated infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acanthamoeba can cause disseminated infection in immunocompromised hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/1\">",
"     1",
"    </a>",
"    ]. The skin and lungs are most frequently affected, with or without CNS involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/106\">",
"     106",
"    </a>",
"    ]. Pulmonary involvement can be bilateral with patchy infiltrates [",
"    <a class=\"abstract\" href=\"UTD.htm?4/41/4762/abstract/106\">",
"     106",
"    </a>",
"    ]. The diagnosis is made by observing trophozoites and cysts in tissue samples. This condition is usually diagnosed postmortem. The optimal approach to treatment is uncertain; combination therapy is warranted. (See",
"    <a class=\"local\" href=\"#H13571725\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13571956\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Free-living amebas are environmental protozoan parasites with worldwide distribution. Four genera cause disease in humans: Naegleria, Acanthamoeba, Balamuthia, and Sappinia. All these species cause central nervous system (CNS) infections, but several species of Acanthamoeba may cause localized infections outside the CNS (in immunocompetent hosts) or disseminated infections (in immunocompromised hosts). (See",
"      <a class=\"local\" href=\"#H13571641\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two CNS clinical syndromes are associated with free-living amebas: primary amebic meningoencephalitis (PAM) caused by",
"      <em>",
"       Naegleria fowleri",
"      </em>",
"      and granulomatous amebic encephalitis (GAE) caused by Acanthamoeba spp,",
"      <em>",
"       Balamuthia mandrillaris,",
"      </em>",
"      and",
"      <em>",
"       Sappinia diploidea",
"      </em>",
"      . (See",
"      <a class=\"local\" href=\"#H13571648\">",
"       'Central nervous system (CNS) infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary amebic meningoencephalitis (PAM) is an acute hemorrhagic meningoencephalitis that occurs primarily in immunocompetent hosts; it resembles acute bacterial meningitis both clinically and in laboratory parameters.",
"      <em>",
"       N. fowleri",
"      </em>",
"      lives in fresh water environments. Transmission to humans occurs primarily through inhalation of infested water, and activities that increase contact of the nasal mucosa with infested water predispose to infection. The diagnosis is established by visualization of amebas in the cerebral spinal fluid (CSF). Few survivors have been reported; therefore, we favor prompt initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (1.5",
"      <span class=\"nowrap\">",
"       mg/kg/day)",
"      </span>",
"      as soon as the diagnosis is considered; empiric initiation of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      and oral rifampicin is also appropriate. (See",
"      <a class=\"local\" href=\"#H13571655\">",
"       'Primary amebic meningoencephalitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acanthamoeba infection is transmitted via inhalation of cysts through the respiratory tract or by direct skin inoculation followed by hematogenous spread. GAE associated with Acanthamoeba almost exclusively occurs in immunocompromised hosts and is characterized by a subacute clinical presentation. The diagnosis is established by brain biopsy. Few survivors have been reported. The optimal approach to treatment is uncertain; combination regimens are preferred over single drug regimens. We favor empiric treatment with a combination of miltefosine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"       pentamidine",
"      </a>",
"      isethionate.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      , and a macrolide (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      ) can be added to this regimen as well. (See",
"      <a class=\"local\" href=\"#H13571697\">",
"       'Acanthamoeba'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <em>",
"       Balamuthia mandrillaris",
"      </em>",
"      is transmitted via contact with soil, and infection can occur among immunocompetent hosts. Two patterns of clinical presentation have been described: some patients develop an initial skin lesion followed by development of the neurologic manifestations in weeks or months, while others present with CNS involvement. (See",
"      <a class=\"local\" href=\"#H13571732\">",
"       'Balamuthia mandrillaris'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early recognition of the Balamuthia skin lesion may facilitate diagnosis and treatment prior to development of CNS involvement; the lesion consists of an asymptomatic non-ulcerated plaque, most commonly on the central face over the nose (",
"      <a class=\"graphic graphic_picture graphicRef88059 \" href=\"UTD.htm?13/5/13397\">",
"       picture 7",
"      </a>",
"      ). Biopsy demonstrates a granulomatous reaction; amebae may be observed and confirmed by immunologic staining or PCR. Balamuthia CNS disease is more difficult to diagnose and has a broader differential diagnosis; brain biopsy may be required. The optimal approach to treatment is uncertain; treatment with multiple drugs for a prolonged duration is warranted. (See",
"      <a class=\"local\" href=\"#H13571732\">",
"       'Balamuthia mandrillaris'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acanthamoeba can cause infection outside the CNS; manifestations include cutaneous infection, nasopharyngeal infection, and keratitis. Keratitis usually occurs among immunocompetent contact lens wearers who do not adhere to proper cleaning procedures, or as a result of direct inoculation following trauma. Clinical manifestations include conjunctival hyperemia, tearing, foreign body sensation, pain, and photophobia. Combination topical therapy should be administered, including polyhexamethylene biguanide or biguanide-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      in combination with propamidine or hexamidine. Debridement may also be warranted. (See",
"      <a class=\"local\" href=\"#H13571774\">",
"       'Infections outside the central nervous system'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5756541\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate Inc. would like to acknowledge Dr. Karin Leder and Dr. Peter Weller, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/1\">",
"      Schuster FL, Visvesvara GS. Free-living amoebae as opportunistic and non-opportunistic pathogens of humans and animals. Int J Parasitol 2004; 34:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/2\">",
"      Visvesvara GS, Moura H, Schuster FL. Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunol Med Microbiol 2007; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/3\">",
"      Qvarnstrom Y, da Silva AJ, Schuster FL, et al. Molecular confirmation of Sappinia pedata as a causative agent of amoebic encephalitis. J Infect Dis 2009; 199:1139.",
"     </a>",
"    </li>",
"    <li>",
"     Visvesvara GS. Free-living amebae as opportunist agents of human disease. J Neuroparasitol 2010; 1:1. file://www.ashdin.com/journals/jnp/N100802.pdf (Accessed on August 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/5\">",
"      Trabelsi H, Dendana F, Sellami A, et al. Pathogenic free-living amoebae: epidemiology and clinical review. Pathol Biol (Paris) 2012; 60:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/6\">",
"      Wellings FM, Amuso PT, Chang SL, Lewis AL. Isolation and identification of pathogenic Naegleria from Florida lakes. Appl Environ Microbiol 1977; 34:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/7\">",
"      Shakoor S, Beg MA, Mahmood SF, et al. Primary amebic meningoencephalitis caused by Naegleria fowleri, Karachi, Pakistan. Emerg Infect Dis 2011; 17:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/8\">",
"      Yoder JS, Straif-Bourgeois S, Roy SL, et al. Primary amebic meningoencephalitis deaths associated with sinus irrigation using contaminated tap water. Clin Infect Dis 2012; 55:e79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/9\">",
"      Ugonabo JA, Gugnani HC. Nasal carriage of Naegleria fowleri and its environmental occurrence in Borno State, Nigeria. J Commun Dis 1989; 21:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/10\">",
"      Kemble SK, Lynfield R, DeVries AS, et al. Fatal Naegleria fowleri infection acquired in Minnesota: possible expanded range of a deadly thermophilic organism. Clin Infect Dis 2012; 54:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/11\">",
"      Yoder JS, Eddy BA, Visvesvara GS, et al. The epidemiology of primary amoebic meningoencephalitis in the USA, 1962-2008. Epidemiol Infect 2010; 138:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/12\">",
"      Marciano-Cabral F, Cline ML, Bradley SG. Specificity of antibodies from human sera for Naegleria species. J Clin Microbiol 1987; 25:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/13\">",
"      Cursons RT, Brown TJ, Keys EA, et al. Immunity to pathogenic free-living amoebae: role of humoral antibody. Infect Immun 1980; 29:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/14\">",
"      Wellings FM. Amoebic meningoencephalitis. J Fla Med Assoc 1977; 64:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/15\">",
"      Hannafin B, LoVecchio F, Rosenberg D. Update on emerging infections: News from the Centers for Disease Control and Prevention. Primary amebic meningoencephalitis-Arizona, Florida, and Texas, 2007. Ann Emerg Med 2009; 54:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/16\">",
"      Qvarnstrom Y, Visvesvara GS, Sriram R, da Silva AJ. Multiplex real-time PCR assay for simultaneous detection of Acanthamoeba spp., Balamuthia mandrillaris, and Naegleria fowleri. J Clin Microbiol 2006; 44:3589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/17\">",
"      Singh P, Kochhar R, Vashishta RK, et al. Amebic meningoencephalitis: spectrum of imaging findings. AJNR Am J Neuroradiol 2006; 27:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/18\">",
"      Ma P, Visvesvara GS, Martinez AJ, et al. Naegleria and Acanthamoeba infections: review. Rev Infect Dis 1990; 12:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/19\">",
"      Cervantes-Sandoval I, Serrano-Luna Jde J, Garc&iacute;a-Latorre E, et al. Characterization of brain inflammation during primary amoebic meningoencephalitis. Parasitol Int 2008; 57:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/20\">",
"      Lopez C, Budge P, Chen J, et al. Primary amebic meningoencephalitis: a case report and literature review. Pediatr Emerg Care 2012; 28:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/21\">",
"      Schuster FL, Visvesvara GS. Opportunistic amoebae: challenges in prophylaxis and treatment. Drug Resist Updat 2004; 7:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/22\">",
"      Duma RJ, Rosenblum WI, McGehee RF, et al. Primary amoebic meningoencephalitis caused by Naegleria. Two new cases, response to amphotericin B, and a review. Ann Intern Med 1971; 74:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/23\">",
"      Goswick SM, Brenner GM. Activities of therapeutic agents against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. J Parasitol 2003; 89:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/24\">",
"      Ferrante A. Comparative sensitivity of Naegleria fowleri to amphotericin B and amphotericin B methyl ester. Trans R Soc Trop Med Hyg 1982; 76:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/25\">",
"      Seidel JS, Harmatz P, Visvesvara GS, et al. Successful treatment of primary amebic meningoencephalitis. N Engl J Med 1982; 306:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/26\">",
"      Vargas-Zepeda J, G&oacute;mez-Alcal&aacute; AV, V&aacute;squez-Morales JA, et al. Successful treatment of Naegleria fowleri meningoencephalitis by using intravenous amphotericin B, fluconazole and rifampicin. Arch Med Res 2005; 36:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/27\">",
"      Gautam PL, Sharma S, Puri S, et al. A rare case of survival from primary amebic meningoencephalitis. Indian J Crit Care Med 2012; 16:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/28\">",
"      Yadav D, Aneja S, Dutta R, et al. Youngest survivor of naegleria meningitis. Indian J Pediatr 2013; 80:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/29\">",
"      Akpek G, Uslu A, Huebner T, et al. Granulomatous amebic encephalitis: an under-recognized cause of infectious mortality after hematopoietic stem cell transplantation. Transpl Infect Dis 2011; 13:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/30\">",
"      Reddy R, Vijayasaradhi M, Uppin MS, et al. Acanthamoeba meningoencephalitis in an immunocompetent patient: an autopsy case report. Neuropathology 2011; 31:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/31\">",
"      Walochnik J, Aichelburg A, Assadian O, et al. Granulomatous amoebic encephalitis caused by Acanthamoeba amoebae of genotype T2 in a human immunodeficiency virus-negative patient. J Clin Microbiol 2008; 46:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/32\">",
"      Booton GC, Visvesvara GS, Byers TJ, et al. Identification and distribution of Acanthamoeba species genotypes associated with nonkeratitis infections. J Clin Microbiol 2005; 43:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/33\">",
"      Pietrucha-Dilanchian P, Chan JC, Castellano-Sanchez A, et al. Balamuthia mandrillaris and Acanthamoeba amebic encephalitis with neurotoxoplasmosis coinfection in a patient with advanced HIV infection. J Clin Microbiol 2012; 50:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/34\">",
"      Marciano-Cabral F, Cabral G. Acanthamoeba spp. as agents of disease in humans. Clin Microbiol Rev 2003; 16:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/35\">",
"      Petry F, Torzewski M, Bohl J, et al. Early diagnosis of Acanthamoeba infection during routine cytological examination of cerebrospinal fluid. J Clin Microbiol 2006; 44:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/36\">",
"      Visvesvara GS, Mirra SS, Brandt FH, et al. Isolation of two strains of Acanthamoeba castellanii from human tissue and their pathogenicity and isoenzyme profiles. J Clin Microbiol 1983; 18:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/37\">",
"      Khan NA. Acanthamoeba: biology and increasing importance in human health. FEMS Microbiol Rev 2006; 30:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/38\">",
"      MacLean RC, Hafez N, Tripathi S, et al. Identification of Acanthamoeba sp. in paraffin-embedded CNS tissue from an HIV+ individual by PCR. Diagn Microbiol Infect Dis 2007; 57:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/39\">",
"      Khan NA. Acanthamoeba and the blood-brain barrier: the breakthrough. J Med Microbiol 2008; 57:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/40\">",
"      Mayer PL, Larkin JA, Hennessy JM. Amebic encephalitis. Surg Neurol Int 2011; 2:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/41\">",
"      Duma RJ, Finley R. In vitro susceptibility of pathogenic Naegleria and Acanthamoeba speicies to a variety of therapeutic agents. Antimicrob Agents Chemother 1976; 10:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/42\">",
"      Stevens AR, Willaert E. Drug sensitivity and resistance of four Acanthamoeba species. Trans R Soc Trop Med Hyg 1980; 74:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/43\">",
"      Ferrante A, Rowan-Kelly B, Thong YH. In vitro sensitivity of virulent Acanthamoeba culbertsoni to a variety of drugs and antibiotics. Int J Parasitol 1984; 14:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/44\">",
"      Slater CA, Sickel JZ, Visvesvara GS, et al. Brief report: successful treatment of disseminated acanthamoeba infection in an immunocompromised patient. N Engl J Med 1994; 331:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/45\">",
"      Seijo Martinez M, Gonzalez-Mediero G, Santiago P, et al. Granulomatous amebic encephalitis in a patient with AIDS: isolation of acanthamoeba sp. Group II from brain tissue and successful treatment with sulfadiazine and fluconazole. J Clin Microbiol 2000; 38:3892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/46\">",
"      Walia R, Montoya JG, Visvesvera GS, et al. A case of successful treatment of cutaneous Acanthamoeba infection in a lung transplant recipient. Transpl Infect Dis 2007; 9:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/47\">",
"      Aichelburg AC, Walochnik J, Assadian O, et al. Successful treatment of disseminated Acanthamoeba sp. infection with miltefosine. Emerg Infect Dis 2008; 14:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/48\">",
"      Lackner P, Beer R, Broessner G, et al. Acute granulomatous acanthamoeba encephalitis in an immunocompetent patient. Neurocrit Care 2010; 12:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/49\">",
"      Sheng WH, Hung CC, Huang HH, et al. First case of granulomatous amebic encephalitis caused by Acanthamoeba castellanii in Taiwan. Am J Trop Med Hyg 2009; 81:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/50\">",
"      Maritschnegg P, Sovinz P, Lackner H, et al. Granulomatous amebic encephalitis in a child with acute lymphoblastic leukemia successfully treated with multimodal antimicrobial therapy and hyperbaric oxygen. J Clin Microbiol 2011; 49:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/51\">",
"      Visvesvara GS, Martinez AJ, Schuster FL, et al. Leptomyxid ameba, a new agent of amebic meningoencephalitis in humans and animals. J Clin Microbiol 1990; 28:2750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/52\">",
"      Visvesvara GS, Schuster FL, Martinez AJ. Balamuthia mandrillaris, N. G., N. Sp., agent of amebic meningoencephalitis in humans and other animals. J Eukaryot Microbiol 1993; 40:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/53\">",
"      Diaz JH. The public health threat from Balamuthia mandrillaris in the southern United States. J La State Med Soc 2011; 163:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/54\">",
"      Reed RP, Cooke-Yarborough CM, Jaquiery AL, et al. Fatal granulomatous amoebic encephalitis caused by Balamuthia mandrillaris. Med J Aust 1997; 167:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/55\">",
"      Kodet R, Noh&yacute;nkov&aacute; E, Tich&yacute; M, et al. Amebic encephalitis caused by Balamuthia mandrillaris in a Czech child: description of the first case from Europe. Pathol Res Pract 1998; 194:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/56\">",
"      Sangruchi T, Martinez AJ, Visvesvara GS. Spontaneous granulomatous amebic encephalitis: report of four cases from Thailand. Southeast Asian J Trop Med Public Health 1994; 25:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/57\">",
"      Campos P, Cabrera J, Gotuzzo E, Guill&eacute;n D. [Neurological involvement in free living amebiasis]. Rev Neurol 1999; 29:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/58\">",
"      Recavarren-Arce S, Velarde C, Gotuzzo E, Cabrera J. Amoeba angeitic lesions of the central nervous system in Balamuthia mandrilaris amoebiasis. Hum Pathol 1999; 30:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/59\">",
"      Galarza C, Larrea P, Kumakawa H. Amebiasis Cut&aacute;nea de Vida libre. Primer caso reportado en el Hospital Dos de Mayo, Lima, Per&uacute;. Dermatolog&iacute;a Peruana 1997; 7:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/60\">",
"      Ballona R, Aquije M. Compromiso cut&aacute;neo en encefalitis granulomatosa  amebiana fatal causada por Balamuthia mandrillaris. Folia Dermatologica Peruana 2003; 14:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/61\">",
"      Taratuto AL, Monges J, Acefe JC, et al. Leptomyxid amoeba encephalitis: report of the first case in Argentina. Trans R Soc Trop Med Hyg 1991; 85:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/62\">",
"      Galarza M, Cuccia V, Sosa FP, Monges JA. Pediatric granulomatous cerebral amebiasis: a delayed diagnosis. Pediatr Neurol 2002; 26:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/63\">",
"      Mart&iacute;nez AJ, Guerra AE, Garc&iacute;a-Tamayo J, et al. Granulomatous amebic encephalitis: a review and report of a spontaneous case from Venezuela. Acta Neuropathol 1994; 87:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/64\">",
"      Gonz&aacute;lez-Alfonzo JE, Mart&iacute;nez AJ, Garc&iacute;a V, et al. Granulomatous encephalitis due to a leptomyxid amoeba. Trans R Soc Trop Med Hyg 1991; 85:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/65\">",
"      Riestra-Castaneda JM, Riestra-Castaneda R, Gonzalez-Garrido AA, et al. Granulomatous amebic encephalitis due to Balamuthia mandrillaris (Leptomyxiidae): report of four cases from Mexico. Am J Trop Med Hyg 1997; 56:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/66\">",
"      Chimelli L, Hahn MD, Scaravilli F, et al. Granulomatous amoebic encephalitis due to leptomyxid amoebae: report of the first Brazilian case. Trans R Soc Trop Med Hyg 1992; 86:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/67\">",
"      Silva-Vergara ML, Da Cunha Colombo ER, De Figueiredo Vissotto E, et al. Disseminated Balamuthia mandrillaris amoeba infection in an AIDS patient from Brazil. Am J Trop Med Hyg 2007; 77:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/68\">",
"      Cuevas P M, Smoje P G, Jofr&eacute; M L, et al. [Granulomatous amoebic meningoencephalitis by Balamuthia mandrillaris: case report and literature review]. Rev Chilena Infectol 2006; 23:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/69\">",
"      Odd&oacute; B D, Ciani A S, Vial C P. [Granulomatous amebic encephalitis caused by Balamuthia mandrillaris. First case diagnosed in Chile]. Rev Chilena Infectol 2006; 23:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/70\">",
"      Schuster FL, Glaser C, Honarmand S, et al. Balamuthia amebic encephalitis risk, Hispanic Americans. Emerg Infect Dis 2004; 10:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/71\">",
"      Niyyati M, Lorenzo-Morales J, Rezaeian M, et al. Isolation of Balamuthia mandrillaris from urban dust, free of known infectious involvement. Parasitol Res 2009; 106:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/72\">",
"      Dunnebacke TH, Schuster FL, Yagi S, Booton GC. Balamuthia mandrillaris from soil samples. Microbiology 2004; 150:2837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/73\">",
"      Ahmad AF, Andrew PW, Kilvington S. Development of a nested PCR for environmental detection of the pathogenic free-living amoeba Balamuthia mandrillaris. J Eukaryot Microbiol 2011; 58:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/74\">",
"      Schuster FL, Dunnebacke TH, Booton GC, et al. Environmental isolation of Balamuthia mandrillaris associated with a case of amebic encephalitis. J Clin Microbiol 2003; 41:3175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/75\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: transplant-transmitted Balamuthia mandrillaris --- Arizona, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1182.",
"     </a>",
"    </li>",
"    <li>",
"     Bravo FG, Cabrera J, Gotuzzo E, et al. Cutaneous manifestations of infection by free living amebas, with special emphasis on Balamuthia mandrillaris. In: Tropical Dermatology, Tyring SK, Lupi O, Henage UR (Eds), 2005. p.49.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/77\">",
"      Pritzker AS, Kim BK, Agrawal D, et al. Fatal granulomatous amebic encephalitis caused by Balamuthia mandrillaris presenting as a skin lesion. J Am Acad Dermatol 2004; 50:S38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/78\">",
"      Schuster FL, Yagi S, Gavali S, et al. Under the radar: balamuthia amebic encephalitis. Clin Infect Dis 2009; 48:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/79\">",
"      Guarner J, Bartlett J, Shieh WJ, et al. Histopathologic spectrum and immunohistochemical diagnosis of amebic meningoencephalitis. Mod Pathol 2007; 20:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/80\">",
"      Yagi S, Schuster FL, Visvesvara GS. Demonstration of Balamuthia and Acanthamoeba mitochondrial DNA in sectioned archival brain and other tissues by the polymerase chain reaction. Parasitol Res 2008; 102:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/81\">",
"      Healy JF. Balamuthia amebic encephalitis: radiographic and pathologic findings. AJNR Am J Neuroradiol 2002; 23:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/82\">",
"      Mart&iacute;nez DY, Seas C, Bravo F, et al. Successful treatment of Balamuthia mandrillaris amoebic infection with extensive neurological and cutaneous involvement. Clin Infect Dis 2010; 51:e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/83\">",
"      Schuster FL, Guglielmo BJ, Visvesvara GS. In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri. J Eukaryot Microbiol 2006; 53:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/84\">",
"      Cary LC, Maul E, Potter C, et al. Balamuthia mandrillaris meningoencephalitis: survival of a pediatric patient. Pediatrics 2010; 125:e699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/85\">",
"      Doyle JS, Campbell E, Fuller A, et al. Balamuthia mandrillaris brain abscess successfully treated with complete surgical excision and prolonged combination antimicrobial therapy. J Neurosurg 2011; 114:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/86\">",
"      Orozco L, Hanigan W, Khan M, et al. Neurosurgical intervention in the diagnosis and treatment of Balamuthia mandrillaris encephalitis. J Neurosurg 2011; 115:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/87\">",
"      Walochnik J, Wylezich C, Michel R. The genus Sappinia: history, phylogeny and medical relevance. Exp Parasitol 2010; 126:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/88\">",
"      De Jonckheere JF. Origin and evolution of the worldwide distributed pathogenic amoeboflagellate Naegleria fowleri. Infect Genet Evol 2011; 11:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/89\">",
"      Marciano-Cabral F. Free-living amoebae as agents of human infection. J Infect Dis 2009; 199:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/90\">",
"      Gelman BB, Rauf SJ, Nader R, et al. Amoebic encephalitis due to Sappinia diploidea. JAMA 2001; 285:2450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/91\">",
"      Gonzalez MM, Gould E, Dickinson G, et al. Acquired immunodeficiency syndrome associated with Acanthamoeba infection and other opportunistic organisms. Arch Pathol Lab Med 1986; 110:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/92\">",
"      Galarza C, Ramos W, Gutierrez EL, et al. Cutaneous acanthamebiasis infection in immunocompetent and immunocompromised patients. Int J Dermatol 2009; 48:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/93\">",
"      Helton J, Loveless M, White CR Jr. Cutaneous acanthamoeba infection associated with leukocytoclastic vasculitis in an AIDS patient. Am J Dermatopathol 1993; 15:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/94\">",
"      Gee SN, Rothschild B, Click J, et al. Tender ulceronecrotic nodules in a patient with leukemia. Cutaneous acanthamebiasis. Arch Dermatol 2011; 147:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/95\">",
"      Dunand VA, Hammer SM, Rossi R, et al. Parasitic sinusitis and otitis in patients infected with human immunodeficiency virus: report of five cases and review. Clin Infect Dis 1997; 25:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/96\">",
"      Rivera MA, Padhya TA. Acanthamoeba: a rare primary cause of rhinosinusitis. Laryngoscope 2002; 112:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/97\">",
"      Jasim H, Knox-Cartwright N, Cook S, Tole D. Increase in acanthamoeba keratitis may be associated with use of multipurpose contact lens solution. BMJ 2012; 344:e1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/98\">",
"      Verani JR, Lorick SA, Yoder JS, et al. National outbreak of Acanthamoeba keratitis associated with use of a contact lens solution, United States. Emerg Infect Dis 2009; 15:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/99\">",
"      Fraser MN, Wong Q, Shah L, et al. Characteristics of an Acanthamoeba keratitis outbreak in British Columbia between 2003 and 2007. Ophthalmology 2012; 119:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/100\">",
"      Mannis MJ, Tamaru R, Roth AM, et al. Acanthamoeba sclerokeratitis. Determining diagnostic criteria. Arch Ophthalmol 1986; 104:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/101\">",
"      Wilhelmus KR, Osato MS, Font RL, et al. Rapid diagnosis of Acanthamoeba keratitis using calcofluor white. Arch Ophthalmol 1986; 104:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/102\">",
"      Ikeda Y, Miyazaki D, Yakura K, et al. Assessment of real-time polymerase chain reaction detection of Acanthamoeba and prognosis determinants of Acanthamoeba keratitis. Ophthalmology 2012; 119:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/103\">",
"      Seal DV. Acanthamoeba keratitis update-incidence, molecular epidemiology and new drugs for treatment. Eye (Lond) 2003; 17:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/104\">",
"      Lim N, Goh D, Bunce C, et al. Comparison of polyhexamethylene biguanide and chlorhexidine as monotherapy agents in the treatment of Acanthamoeba keratitis. Am J Ophthalmol 2008; 145:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/105\">",
"      Kaiserman I, Bahar I, McAllum P, et al. Prognostic factors in Acanthamoeba keratitis. Can J Ophthalmol 2012; 47:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/41/4762/abstract/106\">",
"      Kaul DR, Lowe L, Visvesvara GS, et al. Acanthamoeba infection in a patient with chronic graft-versus-host disease occurring during treatment with voriconazole. Transpl Infect Dis 2008; 10:437.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5687 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-7E15F350EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_41_4762=[""].join("\n");
var outline_f4_41_4762=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13571956\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13571641\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13571648\">",
"      CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13571655\">",
"      Primary amebic meningoencephalitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13571662\">",
"      - Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13571669\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13571676\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13571683\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13571690\">",
"      Granulomatous amebic encephalitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13571697\">",
"      - Acanthamoeba",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13571704\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13571711\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13571718\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13571725\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13571732\">",
"      - Balamuthia mandrillaris",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13571739\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13571746\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13571753\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13571760\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13571767\">",
"      - Sappinia pedata",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13571774\">",
"      INFECTIONS OUTSIDE THE CENTRAL NERVOUS SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13571781\">",
"      Cutaneous infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13571788\">",
"      Nasopharyngeal infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13571795\">",
"      Keratitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13571802\">",
"      - Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13571809\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13571816\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13571823\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13571830\">",
"      Disseminated infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13571956\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5756541\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5687\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5687|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/57/32662\" title=\"diagnostic image 1\">",
"      MRI amebic encephalitis due to Balamuthia Mandrillaris",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/63/3058\" title=\"diagnostic image 2\">",
"      Radiologic imaging in Balamuthia mandrillaris amebic infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5687|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/4/27719\" title=\"figure 1\">",
"      Naegleria life cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/55/13174\" title=\"figure 2\">",
"      Acanthamoeba life cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/22/2406\" title=\"figure 3\">",
"      Balamuthia life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5687|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/3/7222\" title=\"picture 1\">",
"      Trophozoites of Naegleria fowleri",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/1/16404\" title=\"picture 2\">",
"      Naegleria fowleri trophozoite",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/26/43431\" title=\"picture 3\">",
"      Pathological findings in PAM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/25/24980\" title=\"picture 4\">",
"      Acanthamoeba trophozoites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/38/1640\" title=\"picture 5\">",
"      Cyst of Acanthamoeba in brain tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/27/37300\" title=\"picture 6\">",
"      Pathologic findings in GAE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/5/13397\" title=\"picture 7\">",
"      Balamuthia skin lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/22/38249\" title=\"picture 8\">",
"      Pathological findings in B mandrillaris amebic infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/62/4069\" title=\"picture 9\">",
"      Sappinia trophozoites",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_41_4763="Insulin sliding scale";
var content_f4_41_4763=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F65550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F65550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Insulin sliding scale",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Blood glucose, mg/dL",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose of regular insulin, units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;200",
"       </td>",
"       <td>",
"        No insulin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        201 to 250",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        251 to 300",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        301 to 350",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        351 to 400",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;400",
"       </td>",
"       <td>",
"        12 and call physician",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_41_4763=[""].join("\n");
var outline_f4_41_4763=null;
var title_f4_41_4764="Nonasthmatic features";
var content_f4_41_4764=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Features suggestive of a diagnosis other than asthma in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        History",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Onset of symptoms in early infancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neonatal respiratory distress +/- ventilatory support",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neonatal neurologic dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intractable wheezing unresponsive to bronchodilators",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wheezing associated with feeding or vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Difficulty swallowing +/- recurrent vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor weight gain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stridor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxygen requirement &gt;1 week after acute attack",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Physical examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Failure to thrive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clubbing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac murmur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stridor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Focal lung signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nasal polyps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crackles on auscultation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyanosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Laboratory features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Focal or persistent chest x-ray abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irreversible airflow obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoxemia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Canny, GJ, Levison, H, Ann Allergy 1990; 64:406.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_41_4764=[""].join("\n");
var outline_f4_41_4764=null;
var title_f4_41_4765="Instructional variables in learning disability";
var content_f4_41_4765=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Instructional variables that affect learning: school accommodations and modifications for children with learning disabilities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Instructional variable",
"      </td>",
"      <td class=\"subtitle1\">",
"       Modifications to accommodate to the requirements of a typical classroom",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       Level of task difficulty",
"      </td>",
"      <td>",
"       Provide alternative books with similar concepts, but written at an easier reading or language level",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Use peer readers",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Provide audiotapes of textbooks",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"6\">",
"       Duration of allotted time",
"      </td>",
"      <td>",
"       Shorten assignments to focus on mastery of key concepts",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Shorten spelling tests to focus on mastery of the most functional words",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Provide additional time to complete a task",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Allow extra time to turn in homework without a penalty",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Permit as much time as necessary to complete tests",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Break long-term assignments into small, sequential steps, with daily monitoring and frequent grading",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"14\">",
"       Level of receptive and expressive language development",
"      </td>",
"      <td>",
"       Use language to match receptive language level of student",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Use simple statements",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Use gestures, diagrams, or models to emphasize meaning",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Reduce speaking tempo",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maintain visual contact",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Provide summaries of chapters",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Use marker to highlight important textbook sections",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Provide the student with a list of discussion questions prior to reading the text",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Use both oral and printed directions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Give directions in a series of short sentences",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Provide visual cues",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Grade spelling separately from content",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Provide possible answers for fill-in-the-blank tests",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Read and explain mathematical story problems",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"5\">",
"       Level of visual-motor integration skills",
"      </td>",
"      <td>",
"       Use worksheets that require minimal writing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Use multiple-choice or fill-in-the-blank questions, rather than an essay",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Provide a print outline of lectures, videotapes, or assignments",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Omit assignments that require copying",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Substitute alternatives for written assignments",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"6\">",
"       Quality of teacher-pupil relationship",
"      </td>",
"      <td>",
"       Modify school rules that may discriminate against the student",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Minimize the use of punishment; provide positive, as well as negative, consequences",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Provide a partial grade based on individual progress or effort",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mark the correct responses rather than the incorrect responses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Evaluate the classroom structure against the student's needs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Focus instruction, when possible, on student's special interests",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_41_4765=[""].join("\n");
var outline_f4_41_4765=null;
var title_f4_41_4766="Differential diagnosis of physical findings sexual abuse 1";
var content_f4_41_4766=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78867%7EPEDS%2F57033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78867%7EPEDS%2F57033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of physical findings in the evaluation of childhood sexual abuse (part 1)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Finding",
"      </td>",
"      <td class=\"subtitle1\">",
"       Differential diagnosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Perineal area (boys or girls)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Perineal inflammation or erythema",
"      </td>",
"      <td>",
"       Candidal infection, pinworms, perianal cellulitis, contact dermatitis, atopic dermatitis, psoriasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Perineal ulcer or vesicular rash*",
"      </td>",
"      <td>",
"       Syphilis, herpes simplex virus, varicella, chanchroid, Behcet's disease, bullous pemphigoid, Epstein-Barr virus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Perineal bruising",
"      </td>",
"      <td>",
"       Mongolian spots, trauma, hemolytic uremic syndrome, Henoch-Schonlein purpura",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Perianal area (boys or girls)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Perianal erythema",
"      </td>",
"      <td>",
"       Encopresis, poor hygiene, pinworms, Group A streptococcal or staphylococcal infection, irritants, trauma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Anal fissures",
"      </td>",
"      <td>",
"       Constipation; perianal irritation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Perianal scar",
"      </td>",
"      <td>",
"       May be caused by medical conditions, such as fissures, or lesions of Crohn's disease, or from previous medical procedures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Venous congestion or pooling",
"      </td>",
"      <td>",
"       Usually due to positioning of child; may be seen in constipation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Flattened anal folds",
"      </td>",
"      <td>",
"       May be caused by relaxation of the anal sphincter or swelling of the perianal tissues from infection or trauma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Anogenital warts&bull;",
"      </td>",
"      <td>",
"       Human papillomavirus, molluscum contagiousum, common warts, skin tags",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Rectal bleeding",
"      </td>",
"      <td>",
"       Hemorrhoids, Crohn's disease, rectal prolapse, rectal tumors; anal trauma or penetration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Anal dilation to less than 2 cm, with or without stool present",
"      </td>",
"      <td>",
"       May be a normal reflex or caused by severe constipation or encopresis, sedation, anesthesia, neuromuscular conditions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Male genitalia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Penile trauma",
"      </td>",
"      <td>",
"       <p>",
"        Hair tourniquet, zipper entrapment injury, straddle injury",
"       </p>",
"       <p>",
"        (history is usually readily available for zipper entrapment and",
"       </p>",
"       <p>",
"        straddle injuries; straddle injuries usually affect the anterior",
"       </p>",
"       <p>",
"        structures)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Penile or scrotal erythema",
"      </td>",
"      <td>",
"       Irritants, infection, trauma",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Cultures for herpes simplex virus type 1 and 2 and syphilis should be obtained.",
"     <br>",
"      <br>",
"       &bull; May need biopsy to confirm diagnosis.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Bays, J, Jenny, C. Genital and",
"     <br>",
"      anal conditions confused with child sexual abuse trauma. Am J Dis Child",
"      <br>",
"       1990; 144:1319. Hymel, KP, Jenny, C. Child sexual abuse. Pediatr Rev",
"       <br>",
"        1996; 17:236. Adams, JA. Evolution of a classification scale: medical",
"        <br>",
"         evaluation of suspected child sexual abuse. Child Maltreat 2001; 6:31.",
"         <br>",
"          Adams, JA. Medical evaluation of suspected child sexual abuse. J",
"          <br>",
"           Pediatr Adolesc Gynecol 2004; 17:191.",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of physical findings in the evaluation of childhood sexual abuse (part 2)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Finding",
"       </td>",
"       <td class=\"subtitle1\">",
"        Differential diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Female genitalia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Excoriation, bleeding, vascular lesions",
"       </td>",
"       <td>",
"        Nonspecific vulvovaginitis, Group A streptococcal vaginitis,",
"lichen sclerosis, lichen simplex chronicus, lichen planus, atopic",
"dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erythema of the vestibule",
"       </td>",
"       <td>",
"        Irritants, infection, trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Increased vascularity of vestibule and hymen",
"       </td>",
"       <td>",
"        Local irritants, normal pattern of nonestrogenized state",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Labial adhesion",
"       </td>",
"       <td>",
"        Irritation or rubbing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Apparent scarring",
"       </td>",
"       <td>",
"        Linea vestibularis (present in 10 percent of normal newborns)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vaginal bleeding",
"       </td>",
"       <td>",
"        Vaginal foreign body, urethral prolapse (causes apparent vaginal bleeding)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vaginal discharge",
"       </td>",
"       <td>",
"        Sexually transmitted infection, vaginal foreign body",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Friability of the posterior fourchette or commissure",
"       </td>",
"       <td>",
"        Irritation, infection, examiner's traction on labia majora",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Perineal bruising or bleeding",
"       </td>",
"       <td>",
"        Straddle injury (history is usually readily available;",
"straddle injuries usually are symmetric and involve the anterior",
"structures)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Genital scarring",
"       </td>",
"       <td>",
"        Female circumcision",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Genital bleeding",
"       </td>",
"       <td>",
"        Trauma, female circumcision",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"3\">",
"        Other vaginal findings",
"       </td>",
"       <td>",
"        Sarcoma botyroides (unique form of embryonal rhabdomyosarcoma",
"that arises within the wall of the bladder or vagina and protrudes from",
"the vagina resembling a bunch of grapes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ureterocoele",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caruncle (small, red, papillary growth, highly vascular, sometimes found in the urinary meatus of females)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Bays, J, Jenny, C. Genital and anal conditions confused with child sexual abuse trauma. Am J Dis Child 1990; 144:1319. Hymel, KP, Jenny, C. Child sexual abuse. Pediatr Rev 1996; 17:236. Adams, JA. Evolution of a classification scale: medical evaluation of suspected child sexual abuse. Child Maltreat 2001; 6:31. Adams, JA. Medical evaluation of suspected child sexual abuse. J Pediatr Adolesc Gynecol 2004; 17:191.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_41_4766=[""].join("\n");
var outline_f4_41_4766=null;
var title_f4_41_4767="Germ tube formation in Candida";
var content_f4_41_4767=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Germ tube formation in Candida albicans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rapid presumptive identification of C. albicans can be made by observing the formation of germ tubes (the initiation of true hyphal growth) when incubated in proteinaceous liquid (eg, serum) at 36&deg;C for two to three hours. Germ tubes show no constriction at their point of origin from the yeast cell.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Wiley Schell, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_41_4767=[""].join("\n");
var outline_f4_41_4767=null;
